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                                   ABSTRACT 
OBJECTIVE:  Trimetazidine   HCL  is  used as an  potential   treatment of 
Angina pectorise. Trimetazidine HCL is the antianginal compound approved for 
clinical use is widely used for treatment of antianginal either alone or in 
combination with other antianginal agents. However, the main limitation to 
therapeutic effectiveness of Trimetazidine is its dose-dependent hematological 
toxicity, low therapeutic index, short biological half-life, and poor 
bioavailability.After oral administration, it is rapidly absorbed from the 
gastrointestinal tract (GIT) exhibiting a peak plasma concentration of 84 ng/ml at 
1.8+/- .7 hrs hours. The biological half-life of Trimetazidine is 6 hours, thus 
necessitating frequent administration (3 to 4 times a day) to maintain constant 
therapeutic drug levels. To reduce the dosing frequency and improve the patient 
compliance by extended release matrix tablets 
METHODS: Trimetazidine HCL 35mg matrix tablets  were prepared by wet 
granulation method. Hydrophilic polymers Hydroxy propyl methyl cellulose K15-
CR, Micro crystalline cellulose, Ethyl cellulose, Metalose, PVP K30 polymer 
matrix system is used to achieve desirable extended release effect. The 9 
formulations of trial batches were taken by different concentration of polymers and 
all the formulations were evaluated physicochemical methods.Preformulation 
studies was performed for all the ingredients and Drug and excipients interaction 
also evaluated by FTIR method. The tablets were compressed by average weight of 
180mg. Inprocess tests like weight uniformity test, hardness, friability, 
disintegration time was performed. 
  
RESULTS:         IR spectra studies revealed that the drug and polymers used were 
compatible. Various formulations of sustained release matrix tablets of 
Trimetazidine HCL were developed using various polymers viz, HPMC K-15CR, 
Hypermellose, Ethyl Cellulose in different proportions and combinations by Wet 
Granulation technique. The tablets were evaluated for physical characterization, in 
vitro swelling behavior, in vitro release study and stability studies. 
                        Results of in vitro release profile indicated that formulation F9 was 
the most promising formulation as the extent of drug release from this formulation 
was high as compared to other formulations. Results of in-vitro swelling study 
indicate that the formulation F9 was having considerable swelling index. Stability 
study was conducted on tablets of Batch F9 stored at 300C (Room Temperature) 
and 400C for one month. Tablets were evaluated for hardness, friability, in-vitro 
release profile and drug content. After one month no significant changes were 
observed in any of the studied parameters during the study period, thus it could be 
concluded that formulation was stable. It was concluded that the tablets of batch F9 
had considerable swelling behaviors and in vitro drug release. Percentage drug 
release  in  8  hr  is  80.77.   It  was  observed  that  tablets  of  batch  F9  followed  the  
Huguchi release profiles.  
                      From the above results and discussion it is concluded that 
formulation of Extended release matrix tablet of Trimetazidine HCL containing 
HPMC K-15 (19.44%) and Hypermellose (19.44%), Ethyl cellulose (19.44%) 
batch F9 can be taken as an ideal or optimized formulation Extended release matrix 
tablet for 8 hour release as it fulfills the requirements for extended release matrix 
tablet.  
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 1.  INTRODUCTION  
 
         Oral route of drug administration is oldest and safest mode of drug 
administration. It posses several advantages. It does not possess the sterility problem and 
minimal risk of damage at the site of administration. It provides accurate dosing without 
assistantship of administration. In conventional oral drug delivery system, there is little or 
no control over release of drug, and effective concentration at the target site can be 
achieved by administration of grossly excessive dosage form. This kind of dosing pattern 
result in constantly changing, unpredictable and often sub or supra therapeutic plasma 
concentration, leading to marked side effects in some cases. Moreover, the rate and extent 
of absorption from conventional formulation may  vary greatly, depending on factor such 
as physiochemical properties of drug, presence of excipients, various physiological 
factors such as presence or absence of food, pH of gastrointestinal tract, G.I. motility etc.   
 
         The above problem can be minimized by oral controlled drug delivery. In oral 
controlled drug delivery the amount of drug release is constantly predetermined and these 
constant releases of drug provide a constant blood plasma level of drug for a therapeutic 
response. The oral controlled drug delivery have many advantage to conventional 
delivery- it decrease the fluctuation of drug plasma concentration, it reduce toxicity, 
provide a sustained effects, reduced the dosing frequency. Apart from other advantage it 
reduces total amount of drug used, improve patient compliance and reduced patient care 
time. 
          
         The disadvantage of oral controlled release product are longer time to achieve 
therapeutic blood concentration, possible increase variation in bioavailability after oral 
administration, enhanced first pass effect, dose dumping, sustained concentration in oral 
dose case, lack of doses flexibility and usually grater expense. 
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         Hydrophilic polymers are widely used in oral controlled drug delivery due to 
their flexibility to produce desirable drug release profile, cost effectiveness, and broad 
regulatory acceptance. Among the hydrophilic polymers, HPMC 
(hydroxyproylmethylcellulose) is the most widely used carrier for the preparation of oral 
controlled drug delivery system due to its properties such as its ability to swell upon 
jellification once contact with water, and its very low toxicity and easy of manufacture, 
the gel becomes a viscous layer acting as a protective barrier to both influx of water and 
efflux of drug in the solution. On the other hand, hydrophobic polymer, such as EC can 
be alternative to the swelling polymers by forming an inert matrix with no physiological 
action  and  stable  at  different  pH  values  and  moisture  levels  when  a  tablet  with  
hydrophobic matrix is placed in the dissolution medium, the drug at surface is released 
quickly, with a possible burst effects, requiring its replacement drug from inner layers 
that must diffuse through the pores until it reaches the surface. 
         
         Physician can achieve several desirable therapeutics advantages by prescribing 
sustained release dosage form. Since, the frequency of drug administration is reduced, 
patient’s compliances can be improved and the drug administration can be made more 
convenient as well. The blood level oscillation characteristics of multiple dosing form of 
conventional dosage form is reduced, because more even blood level is maintained in the 
design of sustained release dosage form. The total amount of drug administered, thus 
maximum availability with a minimum dose. In addition, the safety margin of high 
potency drug can be increased and the incidence of both local and systemic adverse 
effects can be reduced in sensitive patients. Overall, increased administration of sustained 
release dosage form gives increased reliability. 
 
         Sustained release technology is relatively new field and as a consequence, 
research in the field has been extremely fertile and has produced many discoveries. With 
many drugs, the basic goal is to achieve a steady state blood level that is therapeutically 
effective and non-toxic for an extended period of time. 
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        The  design  of  proper  dosage  form  is  an  important  element  to  accomplish  this  
goal. Sustained release, sustained action, prolonged action, controlled release, extended 
action, timed release and depot dosage form are term used to identify drug delivery 
system that are designed to achieve prolonged therapeutic effect by continuously 
releasing medication over an extended period of time after administration of a single 
dose.  In  the  case  of  oral  sustained  released  dosage  form,  an  effect  is  for  several  hours  
depending upon residence time of formulation in the GIT. 
 
 
        Not all the drugs are the suitable candidates for the sustained release dosage 
form. Ideal characteristic of the drug for the sustained release dosage form are; 
 
 Drug should have a shorter half-life as drug with a longer half-life are inherently 
long acting drugs. 
 
 Drug should be absorbed from large portion of gastrointestinal tract, since 
absorption must occur through the gut. 
 
 
 Drug should be having a good solubility profile to be a good candidate for 
sustained release dosage form. 
 
 Dose  of  the  drug  should  not  be  too  large,  as  a  larger  dose  is  to  be  incorporated  
into sustained release dosage form. 
 
 
 
 
 
 
 
 
Introduction 
 
Department of  Pharmaceutics. Page4
 
1.1 POTENTIAL ADVANTAGE OF SUSTAINED RELEASE DOSAGE FORM:  
 
1) Avoid patient’s compliance problem due to reduced frequency of dosing. 
 
2) Blood level oscillation characteristics of multiple dosing of conventional dosage 
form are reduced because a more even blood level is maintained. 
 
3) Employ a less total drug. 
 
4) Minimize or eliminate local or systemic side effects. 
 
5) Minimize drug accumulation with chronic dosing. 
 
6) Obtained less potential of reduction in drug activity with chronic use. 
 
7) Improved efficiency in treatment. 
 
8) Cure or control condition more promptly. 
 
9) Improved control of condition i.e. reduced fluctuation in drug level. 
 
10)  Improved bioavailability of some drugs. 
 
11)  Make a use of special effects, e.g. sustained release aspect for relief of     
       arthritis by dosing before bedtime. 
 
12)  Economy. 
 
13) Overall, administrations of sustained release form enable increased reliability of 
therapy. 
. 
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1.2 MATRIX SYSTEM:  
       
  The matrix system is most often used for a drug-controlled release from a 
pharmaceutical dosage form. Among the innumerable method used in controlled release 
drug from pharmaceutical dosage form, the matrix system is the most frequently applied; 
it  is  release  system for  delay  and  control  of  the  release  of  the  drug  that  is  dissolved  or  
dispersed in a resistant supports to disintegration. 
 
   To define matrix, it is necessary to know the characters that differentiate it from 
other controlled release dosage forms. Hence the following must be considered: 
 
 The chemical nature of support (generally, the support are formed by polymeric 
net) 
 
 The physical state of drug (dispersed under molecular or particulate form or both). 
 
 
 The matrix shape and alteration in volume as a function of time. 
 
 
 The route of administration (oral administration remains the most widely used but 
other routes are adaptable). 
 
 
 The release kinetic model.            
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1.3 THE CLASSIFICATION OF MATRIX SYSTEM: 
 
       Mineral matrix: 
        Drug retained in the support. 
        Drug adsorbed on the support 
 
        Lipidic matrix: 
        Delivery by diffusion. 
        Delivery by surface erosion 
 
       Hydrophillic matrix: 
       Unlimited swelling, delivery by diffusion. 
       Limited swelling controlled delivery through swelling 
 
       Inert matrix: 
       Controlled delivery by diffusion 
       Biodegradable matrix: 
       Non-Lipidic. 
 
1.4 ADVANTAGES OF MATRIX SYSTEM 
         The interest awakened by matrix system in last few years is completely justified in 
view of the major advantages. Among these, the following stand out. With proper control 
of manufacturing process, reproducible release profiles are possible. 
 
        There is no risk of “dumping” of a large part of dose, through the structure makes 
the immediate release of a small amount of active principle unavoidable. 
 
        Their capacity to incorporate active principle is large, which suits them to delivery 
of large dosage           
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1.5 PRINCIPAL OF MODIFIED DRUG RELEASE:  
        Following either of the two principles can modify drug release. 
 
1.5.1 Barrier principal  
        In this method the retardant material is imposed between the drug and elusion 
medium. Drug release is by diffusion of the drug through the barrier and /or erosion of 
the barrier or permeation of the barrier by moisture 
                                                                                 . 
 
 
Figure no.1. 
Barrier mediated models of sustained release dosage form regimen. 
 
 
 
 
 
 A. Drug diffusion through the barrier, 
 B. permeation of barrier by elution media followed by drug dissolution, 
 C. Erosion of barrier releasing drug, 
 D. rupture of permeation of elutiomedia. 
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1.5.2 Embedded matrix: 
        In this drug is dispersed/embedded in a matrix of retardant material that may be 
encapsulated in a particulate form or compressed into the tablet. Drug release occurs by 
permeation of water leaching extraction of diffusion of drug from the matrix and erosion 
of matrix material.     
 
Figure No. 2 
Embedded matrix concept as a mechanism of controlled released in sustained 
release 
 
 
 
 
 
A. dosage form design network model a drug is insoluble in the retardant material.  
 
 
B Drug is soluble in the retardant material. Diffusion profile etc. Characterize drug 
release from matrix system.  
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1.6 SWELLABLE MATRIXS AS SYSTEM FOR ORAL DELIVERY: 
 
         Monolithic devices or matrices represent a substantial part of drug delivery 
systems. Matrices containing swellable polymers are referred to as   
 
        Hydrogel matrices 
        Swellable control release systems. 
        Hydrophillic matrix tablet  
 
         Swellable matrices for oral administration are commonly manufactured as tablet 
by compression of hydrophilic microparticulate polymers. Therefore, the most 
appropriate classification for these systems is swellable matrix tablet. They are 
constituted of a blend of drug and one or more hydrophilic polymers.  
 
         The release of drug from swellable matrix tablet is based on glassy-rubbery 
transition of polymer as a result of water penetration into the matrix. The interaction 
between water, polymer and drug are the primary factors for drug release. However, 
various formulation variables such as polymer grade, drug–polymer ratio, drug solubility 
and drug and polymer particle size, can influence drug release rate to greater or lesser 
degree.  
The  central  element  of  the  mechanism  of  drug  release  in  the  gel  layer  (rubbery  
polymer), which is formed around the matrix. The gel layer is capable of preventing 
matrix disintegration and further rapid water penetration.Water penetration, polymer 
swelling, drug dissolution and diffusion and matrix erosion are phenomenon determining 
gel layer thickness. Finally drug release is controlled by drug diffusion through the gel 
layer and/or by erosion of the gel layer.  
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1.7. MECHANISMS OF DRUG RELEASE FROM MATRIX SYSTEM  
        The  release  of  drug  from  controlled  devices  is  via  dissolution  of  the  matrix  or  
diffusion of drug through the matrix or a combination of the two mechanisms. 
 
1.7.1. Dissolution controlled systems 
        A drug with slow dissolution rate will demonstrate sustaining properties, since the 
release of the drug will be limited by the rate of dissolution. In principle, it would seem 
possible to prepare extended release products by decreasing the dissolution rate of drugs 
that are highly water-soluble. This can be done by: 
 
Preparing an appropriate salt or derivative 
        Coating the drug with a slowly dissolving material – encapsulation dissolution 
control incorporating the drug into a tablet with a slowly dissolving carrier – matrix 
dissolution control (a major disadvantage is that the drug release rate continuously 
decreases with time). 
        The dissolution process can be considered diffusion-layer-controlled, where the rate 
of diffusion from the solid surface to the bulk solution through an unstirred liquid tablet 
is  the  rate-determining  step.  The  dissolution  process  at  steady-state  is  described  by  the  
Noyes-Whitney equation: 
 
Dc/dt = kDA(Cs-C) = D/hA(Cs-C) 
 
        dC -  dissolution rate 
        kd  -  the dissolution rate constant (equivalent to the diffusion coefficient 
                                    Divided by the thickness of the diffusion layer D/h) 
         D  - Diffusion coefficient 
        Cs  -  saturation solubility of the solid 
         C  -  Concentration of solute in the bulk solution 
 
        Equation 1 predicts that the rate of release can be constant only if the following 
parameters are held constant: surface area, diffusion coefficient and diffusion layer 
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thickness and concentration difference. However, under normal conditions, it is unlikely 
that these parameters will remain constant, especially surface area, and this is the case for 
combination diffusion and dissolution systems. 
 
1.7.2. Diffusion controlled systems 
 
        Diffusion systems are characterized by the release rate of a drug being dependent on 
its diffusion through an inert membrane barrier, which is usually a water-insoluble 
polymer. In general, two types or subclasses of diffusion systems are recognized: 
reservoir devices and matrix devices.  
 
1.7.2.1. Reservoir devices 
 
        In these formulations where tablet coating constitutes the main factor in controlling 
drug release. Examples of materials used to control drug release include hardened gelatin, 
methyl or ethyl cellulose, polyhydroxymethacrylate, methacrylate ester copolymers, and 
various waxes. Ethyl cellulose and methacrylate ester copolymers are the most commonly 
used systems in the pharmaceutical industry. 
 
 
Figure3. Schematic representation of a matrix release system 
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1.7.3 Bioerodible and combination diffusion and dissolution system 
        Bioerodible devices constitute a group of system for which mathematical description 
of release kinetics can be quite complex. Bioerodible matrix system consists of the drug 
dispersed in an erodible matrix.  
 
                                                            
  
           
                    Drug dispersed in matrix  
                                  Time = 0 
 
 
   
                  Drug dispersed in matrix  
                                  Time = t 
 
Figure 4: Representation of a Bioerodible matrix system. 
 
        Drug dispersed in the matrix before release at time = 0. At time = t release by drug 
diffusion or matrix erosion has occurred. 
 
        The mechanism of release from simple erodible slab, cylinders, and sphere has been 
described .by Eq. A simple expression describing release from all three of these erodible 
devices is  
M1/M = 1- (1-K0t/C0a)n 
 
        Where  n=3  for  a  sphere,  n=2  for  a  cylinder  and  n=1  for  a  slab.  The  radius  of  a  
sphere, or cylinder, or the half-height of a slab is represented by a. Mt is the mass of a 
drug released at infinite time. As a further complication, these systems can combine 
diffusion and dissolution of both matrix material and the drug. Not only can drug diffuse 
out of the dosage form, but also the matrix itself undergoes a dissolution process. The  
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complexity of the system can arise from the fact that, as the polymer dissolves, the 
diffusional path-length for the drug changes. These usually result in a moving boundary 
diffusion system. Zero order release can occur only if surface erosion occurs and surface 
area dose not change with time. The inherent advantage of such a system is that 
bioerodible property of the matrix dose not result in a ghost matrix. 
  
 
The disadvantages of these matrix systems are that release kinetics is often hard to 
control, since many factors affecting to both the drug and the polymer must be 
considered.  Another  method  for  the  preparation  of  bioerodible  system  is  to  attach  the  
drug directly to the polymer by a chemical bond. Generally, the drug is released from the 
polymer by hydrolysis or enzymatic reaction. This makes control of the rate of release 
somewhat easier. Another advantage of the system is the ability to achieve very high drug 
loading, since the amount of drug placed in the system   is limited only by the available 
sites on the carrier. 
 
 
         A third type, which in this case utilizes a combination of dissolution and diffusion, 
is that of a swelling controlled matrix. In this the drug is dissolved in the polymer, instead 
of an insoluble or erodible polymer. This allows entrance of water which causes 
dissolution of drug and diffusion out of the swollen matrix.  
 
            In these systems the release rate is highly dependent on polymer-swelling rate, 
drug solubility, and the amount of soluble fraction in the matrix. This system usually 
minimizes burst effects, since polymer swelling must occur before drug release. 
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1.8 ADVANTAGES OF HYDROPHILIC MATRIX TABLET  :  
1) With proper control of the manufacturing process, reproducible release profiles 
are possible. The variability associated with them is slightly less than that 
characterizing coated release form. 
2) Structure allows an immediate release of small amount of active principle there is 
no risk of dose dumping. 
3) Their capacity to incorporate active principle is large, which suits them to 
delivery of large doses.  
4) The manufacturing processes are notably simple. Tablet formulation can be done 
via direct compression or by wet granulation techniques. 
5) Large variety of nonexpensives gelling agents is approved for oral use by   the   
Competent official organization. 
6) The safety margin of high-potency drugs can be increased. 
7) The drug release from hydrophilic matrices show a typical time dependent profile 
i.e. decreased drug release with time because of increased diffusion path length.  
 
1.9 FACTORS INFLUENCING THE DRUG RELEASE FROM MATRIX: 
 Choice of matrix material. 
 Amount of drug incorporated in the matrix. 
 Viscosity of the hydrophilic material in aqueous system at a fixed   
 Concentration.  
 Drug: matrix ratio. 
 Tablet hardness, porosity, and density variation. 
 Entrapped air in tablet. 
 Tablet shape and size. 
 Drug particle size. 
 Solubility of drug in aqueous phase. 
 Surfactants and other additives. 
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1.10 TABLET MANUFACTURING METHODS :  
        Tablets are manufactured by wet granulation, Dry granulation or direct compression 
method. 
1] Wet Granulation 
  
         Wet  granulation  is  the  process  in  which  a  liquid  is  added  to  a  powder  in  a  vessel  
equipped with any type of agitation that will produce agglomeration or granules. These 
granules after drying are compressed to form tablet. 
 
2] Dry Granulation 
 
        In this technique, there is no use of liquids. The process involves the formation of 
slugs. Then the slugs are screened or milled to produce granules. The granules formed are 
then compressed to form tablet. 
 
3) Direct compression 
        The term direct compression is used to define the process by which tablet is 
compressed directly from powder blends of active ingredient and suitable excipients, 
which will flow uniformly in the die cavity and forms a firm compact. 
 
1.11 DRUG PROPERTIES RELEVENT TO CONTROLLED RELEASE 
FORMULATIONS  
        The design of controlled - release delivery systems is subject to several variables of 
considerable importance. Among these are the route of drug delivery, the type of delivery 
system, the disease being treated, the patient, the length of therapy and the properties of 
the drug. Each of these variables are interrelated and this imposes certain constrains upon 
choices for the route of delivery, the design of the delivery system and the length of 
therapy. Properties of drugs are very important for designing a sustained release dosage 
form mainly physicochemical and biological properties of the drug are most important. 
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1.11.1 Physicochemical properties: 
 A) Aqueous solubility and pKa:  
         A drug to be absorbed it must be dissolved in the aqueous phase surrounding the 
site of administration and then partition into the absorbing membrane. Two of the most 
important physicochemical properties of a drug that influence its absorptive behavior are 
its  aqueous  solubility  and  if  it  is  a  weak  acid  or  base  its  pKa.  These  properties  pay  an  
influential role in the performance of controlled release systems. 
 
       The aqueous solubility of a drug influences its dissolution rate, which in turn 
establishes its concentration solution and hence the driving force for diffusion across 
membrane. 
 
        Dissolution rate is related to aqueous solubility as shown by the Noyes-Whitney 
equation that, under sink condition is:- 
 
dc/dt = KDACS 
        Where, dc/dt  = Dissolution rate 
                        KD = Dissolution rate constant. 
                         A        = Total surface area of the drug particles.  
                         Cs       = Aqueous saturation solubility of the drug. 
 
        The dissolution rate is constant only if surface area 'A' remain constant, but the 
important point to note is that the initial rate is directly proportional to aqueous solubility 
Cs.  Therefore,  aqueous  solubility  of  a  drug  can  be  used  as  a  first  approximation  of  its  
dissolution rate. Drugs with low aqueous solubility have low dissolution rates and usually 
suffer oral bioavailability problems. 
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       Aqueous solubility of weak acids and bases is governed by the pKa of the compound 
and pH of the medium. 
For weak acid, 
 
St = So (1+ka/[H+]) = So(1+10 pH – pKa)…………...(1) 
 
        Where,  
          St = Total solubility (both ionized and un-ionized forms) of the weak acid     
         So = Solubility of the un - ionized form 
        Ka = Acid Dissociation constant 
        H+ = hydrogen ion concentration of the medium. .  
 
        Equation (1) predicts that the total solubility, st of a weak acid with a given pKa can 
be affected by the pH of the medium. 
For a weak base, 
 
St = So (1+[H+] / Ka = So (1+10 Pka – PH) ……………… (2) 
 
       Where , 
        St = Total solubility (both conjugate acid and free base forms) of the weak base. 
        So = Solubility of the free base form 
        Ka= Acid dissociation constant of the conjugate acid.  
 
        So total solubility, St of a weak base whose conjugate acid has a given pKa, which 
can be affected by the pH of the medium. 
        In general, extremes in the aqueous solubility of a drug are undesirable for 
formulation into controlled release product. A drug with very low solubility and a slow 
dissolution rate will exhibit dissolution limited absorption and yield an inherently 
sustained blood level.  
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        Formulation of such a drug into a controlled release system may not provide 
considerable benefits over conventional dosage forms. Any system upon diffusion of 
drug through a polymer as the rate - limiting step in release would be unsuitable for a 
poorly soluble drug, since the driving force for diffusion is the concentration of drug in 
the polymer or solution, and this concentration would be low.  For a drug with very high 
solubility and a rapid dissolution rate, it is often quite difficult to decrease its dissolution 
rate to slow its absorption. Preparing a slightly soluble form of a drug with normally high 
solubility is, however, one possible method for preparing controlled release dosage 
forms. 
 
B) Partition Coefficient 
 
        Between time that a drug is administered and the time is eliminated from the body, it 
must diffuse through a variety of biological membranes that act primarily as lipid like 
barriers.  
 
       A major criteria in evaluation of the ability of a drug to penetrate these lipid 
membranes is its apparent oil / water partition coefficient defined as 
 
K = C0/CW 
      Where, 
Co = Equilibrium concentration of all forms of the drug e.g ionized and                   
unionized in  an organic phase at equilibrium. 
           Cw =  Equilibrium concentration of all forms in aqueous phase. 
 
        In  general,  drugs  with  extremely  large  values  of  ‘K’  are  very  oil  soluble  and  will  
partition into membrane quite readily. According to Haunch correlation, the logarithm of 
the activity of a drug or its ability to be absorbed and the logarithm of its partition 
coefficient having parabolic relationship. The explanation for this relationship is that the 
activity  of  a  drug  is  a  function  of  its  ability  to  cross  membranes  and  interact  with  the  
receptor.  The more effectively a drug crosses membranes, the greater its activity. The 
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optimum partition coefficient value of a drug in which it most effectively permeates 
membranes and thus shows the greatest activity.    
        The value of K at which optimum activity is observed is approximately 1000/1. 
Drugs with a partition coefficient that is higher or lower than the optimum is, in general, 
poorer candidates for formulation into controlled-release dosage forms. 
 
C) Drug stability 
        One important factor for oral dosage forms is the loss of drug through acid 
hydrolysis and/or metabolism in the GI tract. Since a drug in the solid state undergoes 
degradation a much slower rate than a drug in suspension or solution. It is possible to 
improve significantly the relative bioavailability of a drug that is unstable in the stomach; 
the most appropriate controlling unit would be one that releases its content only in the 
intestine. The reverse in the case for those drugs that are unstable in the environment of 
the intestine, the most appropriate controlling unit in this case would be one that releases 
its contents only in the stomach, so, drugs with significant stability problems in any 
particular area of the GI tract are less suitable for formulation into controlled release 
systems that  deliver  their  content  uniformity  over  the  length  of  the  GI  tract.  Controlled  
drug delivery systems may provide benefits for highly unstable drugs because the drug 
may be protected from enzymatic degradation by incorporation into a polymeric matrix. 
 
D) Protein Binding 
        There are some drugs which having tendency to bind with plasma proteins (e.g. 
Albumin) and causes retention of the drug in the vascular space. The main force of 
attraction responsible for binding is vanderwal forces, hydrogen bonding and electrostatic 
forces. In general, charged compounds, because of electrostatic effects. 
 
       If a drug binds with protein then the distribution of the drug into the extravascular 
space is governed by the equilibrium process of dissociation of the drug from the protein. 
The drug-protein complex can serve therefore as a reservoir in the vascular space for 
controlled drug release to extravascular tissues, but only for those drugs that exhibit a 
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high degree of binding. Thus, the protein binding characteristics of a drug can play a 
significant role in its therapeutic effect, regardless of the type of dosage form.  
 
        Extensive binding to plasma proteins will be evidenced by a long half-life of 
elimination for the  drug and such drugs generally does not required a controlled-release 
dosage form, however, drugs that exhibit a high degree of binding to plasma protein also 
might bind to biopolymers in the GI tract, which could have an influence on controlled-
drug delivery. 
 
E) Molecular size and diffusivity: 
       Drugs in many controlled-release systems must diffuse through a rate controlling 
membranes or matrix. The ability of a drug to diffuse through membranes, it's so called 
diffusivity [diffusion coefficient), is a function of its molecular size (or molecular 
weight). An important influence upon the value of the diffusivity. 'D', in polymers is the 
molecular size for molecular weight) of the diffusing species. For most polymers, it is 
possible to relate logD empirically to some function of molecular size as 
 
Log D = -Sv log V + Kv   = - SM logM + Km 
                      
                    Where, 
   V =  molecular Volume. 
   M  =  molecular weight. 
          SV,Sm,Kv, Km  =  constant 
  
        The value of 'D'  thus is  related to the size and shape of the cavities as well  as size 
and shape of drugs. Generally, values of the diffusion coefficient for intermediate 
molecular, weight drugs, i.e.150 to 400, through flexible polymers range from 10-6 to 10-9 
cm2 / sec, with values on the order of 108 being most common. A value of approximately 
10-6 is typical for these drugs through water as the medium. For drugs with a molecular 
weight greater than 500, the diffusion co-efficient in many polymers frequently are so 
small that they are difficult to quantify, i.e., less than 10-12 cm2/sec. Thus, high 
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molecular weight drugs and/or polymeric drugs should be expected to display very slow 
release kinetics in controlled release devices using diffusion through polymeric 
membranes or matrices as the releasing mechanism. 
 
1.11.2. Formulation variables 
        The physicochemical characteristics of the drug, in particular its aqueous solubility, 
should be considered in the formulation of a matrix system. Other drug properties 
affecting system design include drug stability in the system and at the site of absorption, 
pH-dependent solubility, particle size and specific surface area. 
 
Drug particle size 
       Effect of drug particle size on release is important in the case of moderately soluble 
drugs. In the case of water-soluble aminophylline or propranolol HPMC-based tablet an 
increase  in  drug  particle  size  did  not  significantly  alter  the  release  rate  of  the  drug.  A  
noticeable  effect  was  seen  only  at  a  low drug:  HPMC ratio  and  at  a  large  drug  particle  
size (above 250µm), in this case, rapid dissolution of the water soluble drug would leave 
a  matrix  with  low tortuosity  and  high  porosity.   Another  study  showed that  for  a  given  
effective surface area, diclofenac particle size influenced the release rate from HPMC 
tablet. The smallest particle size of drug dissolved more easily when dissolution medium 
penetrated through the matrix resulting in a greater role for diffusion. The larger particle 
size dissolved less readily and therefore was more prone to erosion at the matrix surface.  
 
Drug: polymer ratio 
        For diclofenac tablet formulated with HPMC, an increase in polymer: drug ratio 
reduced the release rate. This was because an increase in polymer concentration caused 
an increase in the viscosity of the gel (by making it more resistant to drug diffusion and 
erosion) as well as the formation of a gel layer with a longer diffusional path. Diffusional 
release of the water soluble drug metoprolol decreased with increasing HPMC 
incorporation. By varying the polymer level (Methocel® K4M 10-40%), Nellore et al. 
(1998) achieved different metoprolol in vitro release profiles.  
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Polymer type 
        Various grades of commercially available HPMC differ in the relative proportion of 
the hydroxypropyl and methoxyl substitutions; increasing the amount of hydrophilic 
hydroxypropyl groups leads to a faster hydration: Methocel® K >Methocel® E > 
Methocel® F. Generally rapid hydrating Methocel® K grade is preferred, especially for 
highly soluble drugs where a rapid rate of hydration is necessary. It is important to note 
that an inadequate polymer hydration rate may lead to dose dumping, due to quick 
penetration of gastric fluids into the tablet core (Dow Pharmaceutical Excipients, 1996). 
In each grade, for a fixed polymer level, the viscosity of the selected polymer affects the 
diffusional and mechanical characteristics of the matrix. By comparing different 
Methocel® K viscosity grades, the higher viscosity gel layers provided a more tortuous 
and resistant barrier to diffusion, which resulted in slower release of the drug (metoprolol 
HCl). Sung et al. (1996) compared different viscosity grades of HPMC (Methocel® 
K100LV, K4M, K15M, K100M). The fastest release of adinazolam mesilate was 
achieved for the K100LV formulation. The K4M formulation exhibited a slightly greater 
drug release than K15M and K100M. Due to the lack of a significant difference in the 
release profiles between K15M and K100M, the authors suggested a limiting HPMC 
viscosity of 15000cP, above which, if viscosity increased, the release rate would no 
longer decrease. In the case of ethyl cellulose, the findings are completely different. The 
lower viscosity grades of ethyl cellulose are more compressible than the higher viscosity 
grades, resulting in harder tablet and slower release. 
 
Fillers 
        A study the effect of filler (57% of the tablet weight) on a metoprolol formulation at 
20% Methocel® K4M level. They concluded that filler solubility had a limited effect on 
release rate. The release profiles showed a decrease of about 5-7% after 6h, as the filler 
was changed from lactose to lactose – microcrystalline cellulose then to dicalcium 
phosphate dihydrate -microcrystalline cellulose. Addition of soluble fillers enhanced the 
dissolution of soluble drugs by decreasing the tortuosity of the diffusion path of the drug, 
while insoluble fillers like dicalcium phosphate dihydrate got entrapped in the matrix. 
Also, it was assumed that the presence of swelling insoluble filler like microcrystalline 
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cellulose changed the release profile to a small extent due to a change in swelling at the 
tablet surface. Changing the filler from 100% dicalcium phosphate dihydrate to 100% 
lactose resulted in an increase in metoprolol release from Methocel® K100LV tablet at 4, 
6 and 12h this was explained by dissolution of lactose and the consequent reduction in 
the  tortuosity  and  or  gel  strength  of  the  polymer.  Similar  dissolution  profiles  were  
obtained for filler concentration up to 48%. No dose dumping due to stress cracks (Dow 
Pharmaceutical Excipients, 1996) during gelling were observed in the case of insoluble 
fillers. 
 
Polymeric excipients 
        A study reported that non-ionic polymers did not alter drug release significantly 
from HPMC matrices; however, ionic polymers were capable of retarding the release of 
oppositely charged molecules. They studied the effect of polymeric additives (non-ionic 
polyethylene glycol 6000 or ethyl cellulose, cationic diethylaminoethyl dextran, anionic 
sodium carboxymethyl cellulose Na-CMC) on drug release (chlorpheniramine maleate, 
sodium salicylate and potassiumfenoxymethylpenicillin) from HPMC matrix (85%). 
Non-ionic polymers (15% of tablet weight) did not significantly alter the release rates. 
Na-CMC (50% replacement of HPMC) reduced the chlorpheniramine maleate release in 
pH 7 buffer (near zero order release), but not in an acidic medium. There was a 
complexation of the drug with the anionic polymer; which was not possible below pH 3, 
when Na-CMC was in its unionized insoluble form. As a result of the complexation, the 
gel erosion became the prominent release mechanism instead of diffusion. No interaction 
occurred between sodium salicylate and Na-CMC (both anionic). In the presence of 
diethylaminoethyl dextran, sodium salicylate release was slower at pH 7, but not altered 
at pH 1 (when the drug was present in its unionized form). Overall, the effect of ionic 
polymers incorporated into HPMC matrices on the release of oppositely charged drugs 
was small. The drug-polymer ionic complexation approach in designing oral dosage 
formulation for controlled release of buspirone. Anionic exchange polymers sodium 
carboxymethyl cellulose and methacrylic acid /ethylacrylate copolymer were 
recommended based on the complexation affinity and dispersability in the aqueous 
environment of the gastrointestinal tract. The weight ratio of buspirone to anionic 
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exchange polymer varied between 4:1 and 1:6, preferably between 2:1 and 1:4. In 
addition to facilitating the controlled release of buspirone, the formulations increased the 
bioavailability and reduced the inter-individual variability. Therefore, the buspirone-ion 
exchange polymer HPMC tablet permitted enhanced targeting of therapeutic amounts and 
effects of the drug. The addition of anionic polymers (Eudragit® S, Eudragit® L 100-55, 
and Na-CMC) on the release of weakly basic propranolol hydrochloride from HPMC 
matrices. The interaction between propranolol hydrochloride and anionic polymers 
influenced the drug release. The HPMC: anionic polymer ratio also affected the drug 
release. The matrix containing HPMC: Eudragit® L 100-55 (1:1) produced pH-
independent extended release tablet. An optimization procedure to determine the HPMC: 
e-carrageenan ratio (34:30) required for a pH-independent release of chlorpheniramine 
maleate. e-Carrageenan was added to overcome the increase in diffusion path length and 
decrease in the release rate associated with HPMC systems. e-carrageenan was subjected 
to erosion, which was higher at acidic pH. 
 
1.11.3 PROCESS VARIABLES 
A) Compression force:  
        The compression force had a significant effect on tablet hardness; its effect on drug 
release from HPMC tablet was minimal. It could be assumed that the variation in 
compression  force  should  be  closely  related  to  a  change  in  the  porosity  of  the  tablet.  
However, as the porosity of the hydrated matrix is independent of the initial porosity, the 
compression force seems to have little influence on drug release. The changes in 
compression force or crushing strength had minimal effect on drug release from HPMC 
matrix tablet once critical hardness was reached. Increased dissolution rates were 
observed when the tablets were found to be extremely soft, and this phenomenon was 
attributed to a lack of powder compaction, as tablet hardness was only 3 kp. 
 
B) Tablet shape: 
        The size and shape of the tablet for the matrix system undergoing diffusion and 
erosion might impact the drug dissolution rate. Modification of the surface area for 
metoprolol tartrate tablet formulated with Methocel® K100LV from the standard 
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concave shape (0.568 sq. in.) to caplet shape (0.747 sq. in.) showed an approximately 20-
30% increase in dissolution at each time point. Based upon these results, the researchers 
concluded that for maximum uniformity of extended release characteristics, tablet 
matrices should be manufactured to be as spherical as possible, in order to produce the 
minimum release rate, with regard to tablet shape. Varying the aspect ratio (radius/height) 
of  the  HPMC  tablet  is  a  very  easy  and  effective  tool  to  modify  the  release  rate  of  the  
matrix system. 
                   
                     Release rate for tablet with the same volume was higher for flat shape (ratio 
= 20) than regular cylinders (ratio 2) and almost rod-shaped cylinders (ratio 0.2). The 
results were attributed to difference in tablet surface area. A mathematical model was 
proposed  that  could  employ  in  order  to  calculate  the  optimal  aspect  ratio  and  size  of  a  
cylindrical tablet required to achieve a specific release profile. The model takes into 
account Fickian diffusion of water in and drug out of the tablet and swelling; it does not 
take into account dissolution and it cannot be applied for water insoluble drugs, which are 
released by dissolution process. The mathematical model proposed above was then used 
to predict the dissolution rates of propranolol hydrochloride and chlorpheniramine 
maleate (water soluble drugs). 
 
 
C) Tablet size: 
        For tablet having the same aspect ratio and drug concentration, the tablet size had a 
very strong influence on the release rate; within 24 hours, 99.8% was released from the 
small  tablet,  83.1%  from  the  medium  size  and  50.9%  from  the  large  tablet.  It  was  
hypothesized that the smaller tablet released drug more rapidly due to an increased 
surface area per volume. Additionally, it was concluded that larger diffusion pathways 
existed in the larger tablet leading to a decrease in drug release. 
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1.11.4 BIOLOGICAL PROPERTIES 
I) Absorption: 
        The rate, extent and uniformity of absorption of a drug are important factors when 
considering it's formulation into a controlled - release system. Since the rate limiting step 
in drug delivery from a controlled-release system is its release from a dosage form, rather 
than absorption, a rapid rate of absorption of drug relative to its release is essential if the 
'system is to be successful. In case of controlled release dosage form Kr<<< Ka this 
becomes most critical in the case of oral administration. Assuming that the transit time of 
a drug through the absorption half-life should be to 4 hrs. This corresponds to a minimum 
absorption rate constant Ka of 0.17 to 0.23 hr necessary for about 80 to 95 % absorption 
over  a  9  to  12  hr  transit  time.  For  a  drug  with  a  very  rapid  rate  of  absorption,  (i.e.  Ka  
>>0.23  hr-1),  the  above  discussion  implies  that  a  first  order  release  rate  constant  Kr  <  
0.17 hr-1 is likely to result in unacceptable poor bioavailability in many patients. 
Therefore, slowly absorbed drugs will be difficult to formulate into controlled release 
systems where the criteria that Kr <<< Ka must be met. 
 
II) Distribution: 
        The distribution of a drug into vascular and extravascular spaces in the body is an 
important factor in its overall elimination kinetics. Two parameters that are used to 
describe the distribution characteristics of a drug are its apparent volume of distribution 
and the ratio of drug concentration in the tissue is that in plasma at the steady state called 
T/P ratio. The magnitude of the apparent volume of distribution can be used as a guide 
for additional studies and as a predictor for a drug dosing regimen and hence there is  a 
need to employ a controlled-system. 
 
III) Metabolism: 
        Drugs that are significantly metabolized before absorption, either in the lumen or: 
tissue of the intestine can show decreased bioavailability from slower-releasing dosage 
forms. Most intestinal wall enzyme systems are saturable. As the drug is released at a 
slower rate to these regions, less total drug is presented to the enzymatic process during a 
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specific period allowing more complete conversion of drug to its metabolite. Formulation 
of these enzymatically susceptible compounds as prodrug is another viable solution. 
 
IV) Biological Half Life: 
        The usual goal of an oral sustained release product is to maintain therapeutic blood 
levels over an extended period. To this, drug must enter the circulation at approximately 
the same rate at which it is eliminated. The elimination rate is quantitatively described by 
the half-life.  Each drug has its  own characteristics elimination rate,  which is the sum of 
all elimination processes including metabolism, urinary excretion and all other processes 
that permanently remove drug from blood stream. Therapeutic compounds with short 
half-life are excellent candidates for sustained-release preparations, since this can reduce 
dosage frequency.  However, this is limited, in that drugs with very short biological half 
life as it may require excessively large amounts of drug in each dosage unit to maintain 
sustained effect, forcing the dosage form itself to become limitingly large. 
        In general, drugs with half-life shorter than two hrs are poor candidates for sustained 
release preparations. Drugs with long half-life, more than 8 hrs, are also generally does 
not be used in sustaining forms, since their effect is already sustained. 
   
V) Side Effects and Safety Considerations: 
         There are very few drugs whose specific therapeutic concentrations are known. 
Instead, a therapeutic concentration range is listed, with increasing toxic effects expected 
above this range and a fall off in desired therapeutic response observed below the range. 
 
        The most widely used measure of the margin of safety of a drug is its therapeutic               
index, (Tl). 
 
TI =   LD50/ ED50 
       Where,  
         LD50 = median lethal dose 
         ED50 = median effective dose 
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        For very potent drugs, whose therapeutic concentration range is narrow, the value TI 
is small. In general, larger the value of TI, Usually are poor candidates for formulation 
into controlled-release product. A drug is considered to be relatively safe if its TI value 
exceeds 10. 
 
VI) Dose Size: 
        Since a controlled-release system is designed to alleviate repetitive dosing, it is 
naturally contain greater amount of drug that a corresponding conventional dosage form. 
For lose drugs requiring large conventional doses, the volume of sustained dose may be 
so large so to be impractical or unacceptable, depending on the route of administration. 
The same may be true for drugs that require a large release rate from the controlled-
release system, e.g., drugs with shorter half-life. For oral route, the volume of the product 
is limited by patient acceptance. 
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2. AIM AND OBJECTIVE 
 
The aim of this study is to develop the extended release tablet of 
Trimetazidine HCL for the potential treatment of Angina Pectorise. 
  
2.1 REASONS FOR SELECTION OF TRIMETAZIDINE HCL:- 
¾ Trimetazidine HCL (TMZ), the antianginal compound approved for clinical 
use  is  widely  used  for  treatment  of  antianginal  either  alone  or  in  
combination with other antianginal agents. 
¾  However, the main limitation to therapeutic effectiveness of TMZ is its 
dose-dependent hematological toxicity, low therapeutic index, short 
biological half-life, and poor bioavailability.  
¾ After oral administration, it is rapidly absorbed from the gastrointestinal 
tract (GIT) exhibiting a peak plasma concentration of 84 ng/ml at 1.8+/- .7 
hrs hours. The biological half-life of TMZ is 6 hours, thus necessitating 
frequent administration (3 to 4 times a day) to maintain constant therapeutic 
drug levels. 
 
  2.2 REASONS FOR SELECTION OF DOSAGE FORM 
¾ The goal of any drug delivery system is to provide a therapeutic amount of 
drug to the proper site in the body to promptly achieve and maintain the 
defined drug concentration. 
¾  In pharmaceutical practice, drug administration to patient exists in several 
approaches, one of which is conventional, i.e. drug is given several times a 
day, to produce desired therapeutic effect. 
¾  Due to frequent dosing, fluctuation in the drug blood level occurs; hence 
maintenance of defined drug level can be above or below the minimum 
therapeutic level. The conventional tablet provides only a single transient 
release of drug. 
¾ Hence  the  above  potential  problem  can  be  minimized  or  reduced  by  
formulating the drug in release control matrix i.e. sustain release system 
.This system minimizes or eliminates side effects, provide patient 
Aim and Objective
 
Department of Phamaceutics.                                                                                   Page 30 
 
compliance, economically and promptly achieves and maintains the desired 
effect. 
Hence due to above properties, it may be more efficient to deliver 
the drug at a sustained  manner, at a reduced input rate compared with oral 
conventional dose occurring from a conventional release dosage form 
Trimetazidine HCL is available in market, presently. 
 
   2.3 The main objective of present study:- 
¾ The present study  is to investigate the possibility of developing extended 
release dosage form for the drug Trimetazidine Hcl by using combined 
polymers i.e. HPMC k15CR with Ethyl cellulose, Metalose (Hypermellose) 
with Ethyl cellulose, HPMC k15CR with Metalose and Etyl Cellulose in 
different ratios as matrix 
¾  It can be achieved by planning for trails until the desired release pattern is 
obtained. The aim is to evaluate the release profile of drug from fabricated 
extended release matrix tablets. 
 
 
 
 
  

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3. PLAN OF WORK 
I. Literature survey 
 
II. Preformulation studies - 
x Bulk density 
x Tapped density 
x Carr’s Index (Compressibility Index)  
x  Hausner’s Ratio 
x Determnation of  Ȝ max 
x Drug excipients compatibility study by IR spectra 
 
III. Preparation of Matrix tablets by using matrix forming polymers 
x Method 
¾ By Wet granulation method 
 
  IV. Evaluation of Matrix tablets by 
x  Thickness 
x  Hardness 
x  Weight variation 
x  Friability 
x  In-vitro drug release study 
x  Swelling Index 
 
  V. Stability study. 
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4. REVIEW OF LITERATURE 
 
 
Review of literature showed that the matrix formulation for oral administration of 
many drugs are tried using various polymers and other release retardants 
. 
 
P. D. NAKHAT et.al. “Developing sustained release matrix tablets of diclofenac 
sodium  by  using  different  drug:  polymer  ratios.  Xanthan  gum  w  as  used  as  matrix  former,  
and microcrystalline cellulose as diluent. All the lubricated formulations were compressed 
using 8 mm flat faced punches. Hence, Xanthan gum can be used as an effective matrix 
former, to extend the release of diclofenac sodium”. 
 
 
 Chowdary KPR et al. “Olibanum and its resin and carbohydrate fractions were 
evaluated as rate controlling matrix materials in tablets for controlled release of diclofenac. 
Diclofenac matrix tablets were formulated employing olibanum and its resin and 
carbohydrate fractions in different concentrations and the tablets were evaluated for various 
tablet characters including drug release kinetics and mechanism. Diclofenac matrix tablets 
formulated employing olibanum and its resin component provided slow and controlled 
release of diclofenac over more than 24 h. Drug release from the matrix tablets was by 
Fickian diffusion and followed first order kinetics”. 
 
 
 S C Basak et  al. “Monolithic matrix tablets of ambroxol hydrochloride were 
formulated as sustained release tablets employing hydroxypropyl methylcellulose polymer, 
and the sustained release behaviour of the fabricated tablets was investigated. Sustained 
release matrix tablets containing 75 mg ambroxol hydrochloride were developed using 
different drug polymer ratios of hydroxypropyl methylcellulose”. 
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 J.P.G. Brakenhoff et al.  “The effect of age and renal function on the pharmacokinetic 
profile of a modified release tablet of trimetazidine (TMZ MR 35 mg) administered twice 
daily. 
             Methods- Study 1: Twelve healthy elderly subjects (CLcreat 72±8 ml/min, 72±4 years 
mean±SD) and eight young volunteers (CLcreat 134±18 ml/min, 25±8 years) received TMZ 
MR 35 mg b.i.d. (eight doses). Study 2: eight patients with severe renal failure (CLcreat. 17±5 
ml/min, 54±10 years), five patients with moderate renal failure (CLcreat. 39±6 ml/min, 54±15 
years) and eight volunteers (CLcreat. 104±17 ml/min, 53±9 years) received  TMZ MR 35 mg 
b.i.d. (patients: ten doses, volunteers: eight doses). Serial blood and urine samples were 
obtained following administration of the last dose in each study. TMZ plasma and urine 
concentrations were determined by gas chromatography (NPD-detector). The resulting data 
were analysed using standard non-compartmental pharmacokinetic methods”. 
 
 
 Basak SC et al. “Monolithic matrix tablets of ambroxol hydrochloride were 
formulated as sustained release tablets employing hydroxypropyl methylcellulose polymer, 
and the sustained release behaviour of the fabricated tablets was investigated. The results of 
dissolution studies indicated that a decrease in release kinetics of the drug was observed on 
increasing polymer ratio. The mechanism of drug release from the optimized formulation was 
diffusion coupled with erosion (anomalous)”. 
 
 
 
 R.K.Khar et al. “Compressed tablets were prepared from theophylline and guar 
gum. Effect of the viscosity grade of the polymer and polymer content in the tablets on 
release pattern of theophylline was examined in vitro. Release rate was retarded with increase 
in polymer content as well as the viscosity grade of polymer”. 
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M. Marzilli et al. “The efficacy of trimetazidine as an antianginal drug has been 
assessed in randomized, placebo-controlled studies, both as ‘solo’ treatment and in 
combination with betablockers and calcium channel blockers.In patients with chronic angina, 
trimetazidine increases work capacity and delays the appearance of symptoms and ECG  
             changes during exercise. The benefits observed after acute administration are 
maintained in chronic treatment with trimetazidine, which is well tolerated by patients”. 
 
 
 
 Balasubramaniam et  al. “Matrix tablets of cisapride and atenolol were prepared 
with varying proportions of hydroxypropylmethylcellulose of different viscosity grades viz; 
E15,E4M, K4M, And K15M, alone and combinations by wet granulation technique. The 
study also indicated that the amount of drug released decreased with an increase the polymer 
concentration.  The  combination  of  the  different  viscosity  grades  did  not  provide  any  
additional advantage”. 
 
 
 
P D Nakhat et al.  “In the present investigation, an attempt has been made to 
increase therapeutic efficacy, reduce frequency of administration, and improve patient 
compliance, by developing sustained release matrix tablets of diclofenac sodium. Sustained 
release matrix tablets of diclofenac sodium, were developed by using different drug: polymer 
ratios, such as F1 (1:0.12), F2 (1:0.16), F3 (1:0.20), F4 (1:0.24) and F5 (1:0.28). Xanthan 
gum was used as matrix former, and microcrystalline cellulose as diluent. All the lubricated 
formulations were compressed using 8 mm flat faced punches”.  
 
 
 
Haider S.S. et al. “ Sustained release preparetations of metoclopramide HCl were 
prepared using carnauba wax and stearic acid as matrix formers. Granules were prepared by 
melt dispersion method while tablets were made by direct compression”.  
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The fastest release rate was observed at pH 4.5 and the slowest at pH 1.2 which 
coincides with the drug's solubility behavior. The drug release kinetics followed the Higuchi's 
square root model in all cases 
. 
 
 Rathnanand M. et al. studied to develop sustained release matrix tablets of 
Terbutaline Sulphate.The tablets were prepared by wet granulation method using isopropyl 
alcohol with stearyl alcohol as granulating agent. Hydrophilic matrix materials like 
hydroxypropylmethylcellulose(HPMC), hydrophobic polymer such as Eudragit RLPO where 
used in the study. All the formulations exhibited Higuchi-dominated drug release. The 
mechanism of drug release was found to be diffusion controlled. 
   
 
 
Thapa P. et al. studied the effect of different viscosity grade of HPMC and drug 
solubility on in-vitro release from matrix tablets. In addition to release mechanism, the 
release rate and mean dissolution time for propranolol HCl, salicylic acid and furosemide was 
compared using Krosmeyer-peppas equation. The release mechanism was found to be 
predominately diffusion controlled, anomalous, and case II transport type.  
 
 
 
Nashiru Billa et al. studied processing variables at the laboratory and pilot scales that 
can affect hydration rates of xanthan gum matrices containing diclofenac sodium and the rate 
of drug release. Drug release was linear from xanthan gum matrices prepared at the 
laboratory scale and pilot scales; however, release was faster from the pilot scales.  
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M. Helena Amaral et al. “effect of the concentration of hydrophilic (hydroxyl propyl 
methyl cellulose [HPMC] and hydrophobic (hydrogenated castor oil [HCO] products, fillers 
(lactose and dibasic calcium phosphate), and buffers (sodium bicarbonate, calcium carbonate, 
and sodium citrate) on naproxen release rate was studied. 
  
 
 Robert O. Williams III et al. studied a reverse-phase high-performance liquid 
chromatographic (HPLC) method for recovery of the lipophilic drug, alprazolam, from 
matrix tablets containing the hydrophilic polymer hydroxylpropylmethylcellulose (HPMC) 
was developed. The recovery method reported here in was shown to be the most efficient to 
achieve complete recovery of alprazolam from powder blends and tablets containing a variety 
of excipients and different grades of HPMC. 
 
 
 Sandip B. Tiwari et al. studied the effect of concentration of hydrophilic (hy-
droxypropyl methylcellulose [HPMC]) and hydrophobic polymers (hydrogenated castor oil 
[HCO], ethylcellulose) on the release rate of tramadol were studied. Hydrophilic matrix 
tablets were prepared by wet granulation technique, while hydrophobic (wax) matrix tablets 
were prepared by melt granulation technique. Hydro-phobic matrix tablets resulted in 
sustained in vitro drug release (>20 hours) as compared with hydrophilic ma-trix tablets (<14 
hours). The presence of ethylcellulose in either of the matrix systems prolonged the release 
rate of the drug. 
 
 
 
 K. Raghuram Reddy et al. studied to develop once-daily sustained-release matrix 
tablets of nicorandil, a novel potassium channel opener used in cardiovascular diseases. The 
tablets were prepared by the wet granulation method. Ethanolic solutions of ethylcellulose 
(EC), Eudragit RL-100, Eudragit RS-100, and polyvinylpyrrolidone were used as granulating 
agents along with hydrophilic matrix materials like hydroxypropyl methylcellulose (HPMC), 
sodium carboxymethylcellulose, and sodium alginate. The results of dissolution stud-ies 
indicated that formulation (drug-to-HPMC, 1:4; ethanol as granulating agent) could extend 
the drug release up to 24 hours.  
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 Svetlana Ibric et al.   studied  to model the effects of the concentration of Eudragit L 
100 and compression pressure as the most important process and formulation variables on the 
in vitro release pro-file of aspirin from matrix tablets formulated with Eudragit L 100 as 
matrix substance and to optimize the formulation by artificial neural network. 
 
 
 Srisagul Sungthongjeen et al. “Effect  of  2  formula-tion  variables,  the  pectin  type  
(with different degrees of es-terification [DEs] and the amount of calcium, on drug re-lease 
from pectin-based matrix tablets. The results were more pronounced in phosphate buffer, 
where the phosphate ions induced the pre-cipitation of calcium phosphate. In conclusion, 
both pectin type and added calcium affect the drug release from the pec-tin-based matrix 
tablets”. 
 
 
 Meena Rani et al. studied to Prepared and comparative evaluation of fabricated 
matrix (FM), osmotic matrix (OM), and osmotic pump (OP) tablets for controlled delivery of 
diclofenac sodium (DS). It was concluded that the osmotic matrix and osmotic pump tablets 
could provide more prolonged, controlled, and gastrointestinal environmental independent 
DS release that may result in an improved therapeutic efficacy and patient compliance. 
 
 
 Saleh M. Al-Saidan et al. “Develop guar gum matrix tablets for oral controlled 
release of water-soluble diltiazem hydrochloride. Matrix tablets of diltiazem hydrochloride, 
using various viscosity grades of guar gum in 2 proportions, were prepared by wet 
granulation method and subjected to in vitro drug release studies. Based on the results of in 
vitro and in vivo studies it was concluded that that guar gum matrix tablets provided oral 
controlled release of water-soluble diltiazem hydrochloride”. 
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Mohammad Reza Siahi et al.  “Design oral controlled delivery systems for the 
water-soluble drug, verapamil hydrochloride, using natural and semisynthetic polymers as 
carriers in the forms of 1- and 3-layer matrix tablets. Verapamil hydrochloride 1-layer matrix 
tablets containing hydroxylpropylmethylcellulose, tragacanth, and acacia either alone or 
mixed were prepared by direct compression technique.  
 
The results also showed that the location of the polymers in the 3-layer tablets has a 
pronounced effect on the drug release. Kinetic analysis of drug release from matrices 
exhibiting sustained release indicated that release was predominantly attributable to the 
contribution made by Fickian diffusion, while the erosion/relaxation mechanisms had a minor 
role in the release”. 
 
 
 
 
 Bhupinder Singh et al.  Design oral controlled release mucoadhesive compressed 
hydrophilic matrices of atenolol and to optimize the drug release profile and bioadhesion 
using response surface methodology. A central composite design for 2 factors at 3 levels each 
was employed to systematically optimize drug release profile and bioadhesive strength. 
Carbopol 934P and sodium carboxy methyl cellulose were taken as the independent 
variables. Besides unraveling the effect of the 2 factors on the various response variables, the 
study helped in finding the optimum formulation with excellent bioadhesive strength and 
controlled release. 
 
 
 
 
 Jaleh Varshosaz et al.  developed matrix sustained release tablets of highly water-
soluble tramadol HCl using natural gums (xanthan [X gum] and guar [G gum]) as 
costeffective, nontoxic, easily available, and suitable hydrophilic matrix systems compared 
with the extensively investigated hydrophilic matrices (ie, hydroxypropyl methylcellulose 
[HPMC]/carboxymethyl cellulose [CMC] with respect to in vitro drug release rate) and 
hydration  rate  of  the  polymers.  Tablets  with  only  X  had  the  highest  mean  dissolution  time  
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(MDT), the least dissolution efficiency (DE8%), and released the drug following a zero-order 
model via swelling, diffusion, and erosion mechanisms. Guar gum alone could not efficiently 
control  the  drug  release,  while  X  and  all  combinations  of  natural  gums  with  HPMC  could  
retard tramadol HCl release. However, according to the similarity factor ( f2), pure HPMC 
and H8G2 were the most similar formulations to Topalgic-LP as the reference standard. 
 
 
 
 Carla Martins Lopes et al. was studied to produce a quick/slow biphasic delivery 
system for ibuprofen. A dual component tablet made of a sustained release tableted core and 
an immediate release tableted coat was prepared by direct compression. Both the core and the 
coat contained a model drug (ibuprofen). The sustained release effect was achieved with a 
polymer (hydroxyl propyl methylcellulose [HPMC] or ethyl cellulose) to modulate the 
release of the drug. The in vitro drug release profile from these tablets showed the desired 
biphasic release behavior: the ibuprofen contained in the fast releasing component was 
dissolved within 2 minutes, whereas the drug in the core tablet was released at different times 
§16 or 924 hours), depending on the composition of the matrix tablet. Based on the release 
kinetic parameters calculated, it can be concluded that the HPMC core was suitable for 
providing a constant and controlled release (zero order) for a long period of time. 
 
 
 
 Amelia Avachat et al. Develop and characterize an oral controlled release drug 
delivery system for concomitant administration of diclofenac sodium (DS) and chondroitin 
sulfate (CS). A hydrophilic matrix-based tablet using different concentrations of hydroxyl 
propyl methylcellulose (HPMC) was developed using wet granulation technique to contain 
100 mg of DS and 400 mg of CS. In conclusion, the in vitro release profile and the 
mathematical models indicate that release of CS and DS can be effectively controlled from a 
single tablet using HPMC matrix system.  
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Hamdy Abdelkader et al. was investigating different types and levels of hydrophilic 
matrixing agents, including methylcellulose (MC), sodium alginate (Alg), and sodium 
carboxy methylcellulose (CMC), in an attempt to formulate controlled-release matrix tablets 
containing 25 mg baclofen. The tablets were prepared by wet granulation. Prior to 
compression, the prepared granules were evaluated for flow and compression characteristics. 
In vitro, newly formulated controlled-release tablets were compared with standard 
commercial tablets (Lioresal and baclofen). The prepared matrix tablets showed good 
mechanical properties (hardness and friability). MC- and Alg-based tablet formulations 
showed high release-retarding efficiency, and good reproducibility and stability of the drug 
release  profiles  when  stored  for  6  months  in  ambient  room  conditions,  suggesting  that  MC  
and Alg are good candidates for preparing modified release baclofen tablet formulations 
 
 
 
 Atul Kuksal et al. was studied to prepare and characterize extended-release matrix 
tablets of zidovudine using hydrophilic Eudragit RLPO and RSPO alone or their combination 
with hydrophobic ethyl cellulose. Release kinetics was evaluated by using United States 
Pharmacopeia (USP)-22 type I dissolution apparatus. The in-vitro drug release study revealed 
that either Eudragit preparation was able to sustain the drug release only for 6 hours (94.3% ± 
4.5% release). Combining Eudragit with ethyl cellulose sustained the drug release for 12 
hours (88.1% ± 4.1% release). Fitting the in vitro drug release data to Korsmeyer equation 
indicated that diffusion along with erosion could be the mechanism of drug release. In vivo 
investigation in rabbits showed sustained-release pharmacokinetic profile of zidovudine from 
the matrix tablets formulated using combination of Eudragits and ethylcellulose. In 
conclusion, the results suggest that the developed sustained-release tablets of zidovudine 
could perform therapeutically better than conventional dosage forms, leading to improve 
efficacy and better patient compliance. 
   
 
                 Punna R. R. et al. ,Oral controlled release matrix tablets of zidovudine were 
prepared using different proportions and different viscosity grades of hydroxypropyl 
methylcellulose. The effect of various formulation factors like polymer proportion, polymer 
viscosity and compression force on the in vitro release of drug were studied. In vitro release 
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studies revealed that the release rate decreased with increase in polymer proportion and 
viscosity grade. Mathematical analysis of the release kinetics indicated that the nature of drug 
release from the matrix tablets followed non-Fickian or anomalous release. The developed 
controlled release matrix tablets of zidovudine, with good initial release (17—25% in first 
hour)  and  which  extend  the  release  upto  16—20  h,  can  overcome  the  disadvantages  of  
conventional tablets of zidovudine. 
 
 
 Nokheldchi A. et al.,  The  effects  of  various  polymers  on  the  release  of  Diclofenac  
Sodium from matrics. In vitro release profile of Diclofenac Sodium from ethyl cellulose and 
HPMC K4M matrices showed that decreasing the concentration of Ethyl Cellulose and 
increase in the concentration of HPMC K4M resulted in an increase in the release rate of 
Diclofenac Sodium.   
 
 
 
 B.S. Nath et.al.,The using a combined hydrophobic and hydrophilic matrix on the 
release of  Theophylline. Combination of aliphatic alcohol (cetyl alcohol (cetyl alcohol) 
partially hydrated Methylcellulose was investigated as a sustain release matrix. The in-vitro 
release data showed that the total matrix component gave extended release of Theophylline 
for  more  than  8  hours  and  the  drug  release  from  the  matrix  indicated  that  the  drug  was  
released by diffusion obeying first order rate kinetics. 
   
 
 Chowdary K.P.R. et al. , Sustained release of Nifedipine tablets by using 
soliddispersion in HPMC with HPC and reported that its gave slow, controlled and complete 
release spread over a period of 12 hours. Drug release from these tablets followed zero order 
kinetics and release was by diffusion controlled. 
 
 
 
 M. Helena Amaral et al. , The effect of the concentration of hydrophilic 
(hydroxypropyl methylcellulose [HPMC]) and hydrophobic (hydrogenated castor oil [HCO]) 
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products, fillers (lactose and dibasic calcium phosphate), and buffers (sodium bicarbonate, 
calcium carbonate, and sodium citrate) on naproxen release rate was studied. Matrix tablets 
were prepared by double compression, and In vitro dissolution tests were performed. The 
dissolution results showed that an increased amount of HPMC or hydrogenated castor oil 
resulted in reduced drug release. 
 
 
 Efentakis M., et al. ,The effect of excipients on swelling and drug release from 
compressed matrices. The result showed that mechanisms are affected by the composition of 
matrix. 
 
 
 Efentakis. et al. ,The influence of surfactant on drug release from a hydrophobic 
matrix. Hydrophobic materials were prepared using Eudragit R.L-100 and Flurbiprofen as a 
model drug and studied to determine the mechanism by which surfactant increase the rate of 
drug release. It was concluded that for the matrix the major mechanism by which surfactant 
increase drug dissolution rates is through the formation of pores to aid the access of 
dissolution fluid and egress of the dissolved drug. 
 
 
 Rippe EG, et al. , A stabilized sustained release oral solid dosage form which 
includes an effective amount of tramodol or pharmaceutically acceptable salt therfof 
dispersed in matrix of a hydrophobic material comparising a wax-like substance which was 
melted or softened during the preparation of the matrix,is cured at a temperature from about 
35 0 C to 65 0 C for a time period from about 4 to about 72 hour , such that the  formulation. 
 
 
 Skoug J.W. et al.  ,The quantities evaluation of the mechanism of release of matrix 
sustained release dosage forms by measurement of polymer release. 
   
 
 Hsieh et al. ,Reported a more elegant version of this device which utilized an inward 
releasing hemisphere. This hemisphere was coated with an impermeable membrane barrier 
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everywhere except a small aperture in the center of this circular face. Such a device has been 
applied to polypeptide hormone insulin.  
 
 
 Kawasheina I. et al. ,A modified spherical agglomeration technique as an alternative 
to spray congealing method. The method of preparation will influence the releasing 
characteristics obtained. 
 
 
 
 Chinam Niranjan Patra et al. ,Develop a bilayer tablet of propranolol 
hydrochloride using superdisintegrant sodium starch glycolate for the fast release layer and 
water immiscible polymers such as ethylcellulose, Eudragit RLPO and Eudragit RSPO for 
the sustaining layer. The formulations gave an initial burst effect to provide the loading dose 
of the drug followed by sustained release for 12 h from the sustaining layer of matrix 
embedded tablets. In vitro dissolution kinetics followed the Higuchi model via a non-Fickian 
diffusion controlled release mechanism after the initial burst release 
 
 
 Teerawat Sahasathian et al. ,  The  Sustained  release  systems  in  the  forms  of  
chitosan (CTS) tablet and extrude for releasing amoxicillin. The result showed that chitosan 
with the particle size less than 75 ȝm yielded the best controlled release pattern. Moreover, 
the tablets containing chitosan with particle size less than 75 ȝm were able to provide a 
significantly improved sustained release profile of amoxicillin compared to the release profile 
of a commercial capsule. 
 
 
 S. Prasanna et. al., “To develop “once daily” sustained release tablets of aceclofenac 
by direct compression using hydroxypropyl methylcellulose-K4M (HPMC). The solubility 
studies of aceclofenac were conducted to select suitable dissolution media. The tablets were 
subjected to physicochemical, in vitro drug release and stability studies”. 
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It was observed from the reviewer of literature that very less work has been done on 
the formulation of matrix devices of Zidovudine. So, it was proposed to take Zidovudine in 
the present study of formulation of matrix tablet. Further it was proposed to use Xanthan, 
Ethyl cellulose, Hydroxy propyl methyl cellulose (E.Lv-15), Carboxy Methyl cellulose 
Sodium and Eudragit L155 as polymer is very less work has been done on above polymers. 
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5.1 DRUG PROFILE   
 
Figure No.5:- Structure of Trimetazidine HCL 
 
 Drug Name       : Trimetazidine HCL  
 
Chemical Name: 1-(2, 3, 4-Trimethoxybenzyl) piperazine hydrochloride. (TMZ).  
 
Molecular Formula: (C14H22N2O3 ) 2HCL 
 
Molecular Weight   : 339.26 g/mol. 
 
Category: Antianginal (vasodilator) Trimetazidine (Di HCl) is used in angina and in 
ischaemia of neuro-sensorial tissues.To prevent the pain of chest due to lack of oxygen to the 
muscles of heart. 
Solubility: very soluble in water, sparingly soluble in ethanol and practically insoluble in 
ether. 
 
 Melting Point:  227°C. 
 
 
 
 
Drug and Excipients Profile 
 
Department of Pharmaceutics.                                                                                        Page46
 
PHARMACOKINETICS: 
PHARMACOKINETIC DATA:  
¾ Bioavailability-  90% 
¾ Protein binding –16% 
¾ Metabolism - hepatic 
¾ Half life – 6.0 +/- 1.4 hours 
¾ Excretion -  urinary  
¾ Peak plasma concentration – 84 ng/ml  
¾ T max – 1.8+/- .7 hrs 
¾ Duration of action – 4 hrs or longer 
¾ Volume of distribution is found to be 4.8 l/kg and plasma protien binding is 16 %.  
 
PHARMACOLOGY: 
 Trimetazidine,  known  for  years  to  be  an  effective  antianginal  agent,  shifts  cardiac  
energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial 
long-chain 3-ketoacyl coenzyme A thiolase. By decreasing fatty acid oxidation, trimetazidine 
stimulates glucose utilization, restoring coupling between glycolysis and carbohydrate 
oxidation and leading to adenosine triphosphate production with lesser oxygen consumption. 
The antianginal properties of this agent are devoid of haemodynamic changes, and 
dramatically improve recovery of mechanical function after ischemia. 
 
MECHANISM OF ACTION: 
It has recently been demonstrated that, by inhibiting mitochondrial long-chain 3-
ketoacyl coenzyme A thiolase, trimetazidine alters energy metabolism via inhibitory effects 
on fatty acid oxidation, thus favouring glucose oxidation. On the basis of this recent 
observation, trimetazidine is regarded as the prototype of a new class of antianginal agents: 
the 3-ketoacyl coenzyme A thiolase inhibitors. The benefits of increased glycolytic substrate 
utilization are attributed to a number of mechanisms. The number of moles of adenosine 
triphosphatase (ATP) produced per mole of carbon oxidized is approximately 29% higher for 
free  fatty  acids  relative  to  glucose,  but  the  number  of  moles  of  ATP produced  per  mole  of  
oxygen consumed is 12% higher for glucose than for free fatty acid oxidation. Thus, in 
normal conditions, it is more efficient for the myocardium to utilize free fatty acids, but 
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during ischaemia glucose is a better substrate. By decreasing fatty acid oxidation and 
stimulating glucose utilization, trimetazidine restores coupling between glycolysis and 
carbohydrate oxidation, and leads to ATP production with less oxygen consumption. By 
stimulating membrane phospholipid turnover during ischaemia and reperfusion, trimetazidine 
redirects fatty acids toward phospholipids. 
 
 
 
SIDE EFFECTS: 
Trimetazidine hydrochloride is safe & well tolerated. In addition, the toxic dose being very  
high, the safety margin of this drug is wide. The most commonly encountered side effects are 
gastric discomfort, nausea, headache and vertigo. 
INTERACTIONS: 
No drug interactions so far have been reported .in particular no interactions have 
been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents 
or digitalis praparations.                                                       
 
 
 
5.2 POLYMER PROFILE  
 
1. HYDROXY PROPYL METHYL CELLULOSE K15CR (HPMC K15CR) 
Non-Proprietary Names: 
BP            : Hypromellose  
Ph Eur   : Methyl hydroxy propyl cellulosum  
USP          : Hydroxy propyl methyl cellulose  
Synonyms:  
 Cellulose, hydroxypropyl methyl ether, culminal MHPC; E-464, HPMC; Methocel; 
methyl cellulose propylene glycol ether, methyl hydroxypropylcellulose, Metolose, 
Pharmacoat.  
Chemical Name: Cellulose, 2-hydroxypropyl methyl ether.  
Empirical Formula & Molecular Weight : 
According to European Pharmacopoeia:  
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It is a partly O-methylated & O-(2-hydroxypropylated) cellulose. 
Available in several grades with different viscosity and extent of substitution. Grades 
may be distinguished by appending a no. indicative of the apparent viscosity, in mpas, of a 
2% w/w aqueous solution at 200C.  
According to USP XXII:  
It specifies the substitution type by appending a 4-digit number to a non-proprietary 
name, e.g. HPMC1828. First 2 digits refers approximate % of methoxy group (-OCH3) & last 
2 digits refers approximate % of hydroxy propoxy group (-OCH2CHOHCH3) calculated on 
dried basis. Molecular weight is 10,000-1, 50,000 gm/mol.  
 
 
Functional Category: 
Coating agent, film former, stabilizing agent, suspending agent, tablet binder, 
viscosity – increasing agent. 
Application in Pharmaceutical Formulation / Technology:  
¾ Widely used in oral & topical pharmaceutical formulation.  
¾ In oral product, HPMC is generally used as tablet binder, in film coating & as an 
extended release matrix tablets 2-5% w/w concentration is suitable as binder in either 
wet or dry granulation process.  
¾ High viscosity grades may be used to retard the release of water-soluble drug from 
matrix.  
¾ Depending on viscosity grade concentration between 2-10% w/w used as film forming 
solution to film-coat tablets. Lower viscosity grades are used in aqueous film coating 
solution while higher viscosity grades used with organic solvents.  
¾ Also used as suspending and thickening agent in topical formulation, mainly in 
ophthalmic preparation, as it forms a clear solution with fewer undispersed fibers as 
compared to methylcellulose. So 0.45 –1% w/w used as thickening agent to vehicles for 
eye-drops or artificial tear solution.  
¾ Also used as emulsifier, suspending agent & stability agent in topical gels & ointments. 
As a protective colloid it can also prevent droplets & particles to coalescing or 
agglomerating, thus inhibits sediment formation.   
¾ Also used as adhesive in plastic bandage & wetting agent in topical gels & Ointments. 
As a protective colloid it can also prevent droplets and particles to coalescing or 
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agglomerating, thus inhibits sediment formation. Also used as adhesive in plastic 
bandage & wetting agent for hard contact lenses. Widely used in cosmetics & food 
products. 
 
Description: Odorless & tasteless, white or creamy-white colored fibrous or granular                 
powder.  
 
 
 
Solubility:  
In cold water forms viscous colloidal solution, practically insoluble in chloroform 
(CHCl3), ethanol (95%) & water, but soluble in mixture of ethanol & dichloromethane. 
Incompatibility: 
It is incompatible with some oxidizing agent. As at is nonionic it can’t complex with 
metallic salts and ionic organics to form insoluble points.  
Stability & Stability Condition:  
It is a stable material but hygroscopic after drying. Solutions are stable between pH 3-
11. Increase in temperature decreases viscosity of solution, as it undergoes a reversible sol to 
gel transformation upon heating and cooling respectively and get point is 50-900C. Aqueous 
solutions are enzyme resistant, provide good viscosity during long-term storage, but aqueous 
solution liable to microbial contamination and should be preserved with an antimicrobial 
preservative. Stored in a well-closed container, in cool & dry place.  
 
2. ETHYL CELLULOSE 
Nonproprietary Name:  
BP           : Ethyl Cellulose 
Ph Eur    : Ethyl Cellulosum 
USP NF   : Ethyl Cellulose. 
Synonyms: Aquacoat  ; E462 ; Ethocel ; Surelease. 
Chemical Name: Cellulose ethyl ether.  
Empirical Formula & Molecular Weight: Ethyl  Cellulose  with  complete  ethoxyl  
substitution (DS=3) is C12H23O6 (C12H22O5)n C12H23O5, where “n” can vary to provide a wide 
variety of molecular weights. 
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Functional Category: Coating agent, flavoring agent, viscosity-increasing agent, tablet 
binder, tablet filler. 
Application in Pharmaceutical Formulations: 
¾ Used as a hydrophobic coating agent for tablets & granules. Ethyl cellulose coatings 
are used to modify the release of a drug, to mask unpleasant taste & to improve 
stability. 
¾ Used as a matrix former to produce modified release tablets. 
¾ High viscosity grades are used in drug micro-encapsulation. 
¾ Used as a SR tablet coating material in a concentration of 2-3%. 
¾ Used as thickening agent in topical formulations. 
Description: It is a tasteless, free flowing, white to light tan-colored powder. 
Solubility: Practically insoluble in glycerin, propylene glycol & water. Ethylcellulose that 
contains less than 46.5% ethoxyl group is freely soluble in chloroform, methyl acetate & 
tetrahydrofuran, in mixtures of aromatic hydrocarbon with ethanol (95%). Ethylcellulose that 
contains not less than 46.5% ethoxyl group is freely soluble in chloroform,ethanol (95%), 
ethyl acetate, methanol & toluene 
Viscosity: Viscosity increases with an increase in the ethyl cellulose concentration. 
Incompatibilities: Incompatible with paraffin wax & microcrystalline wax. 
Stability & Storage Conditions: It shows oxidative degradation in presence of sunlight or 
UV light at elevated temperatures, which can be prevented by the use of anti-oxidants & 
additives that can absorb light at 230-340nm range. It should be stored at a temp. not 
exceeding 32°C (90°F). It shouldn’t be stored next to peroxides of other oxidizing agents. 
 
3. METALOSE 
Non-Proprietary Name:  
               USP:    Hypermellose 
               Substitution Type:         2208 
               Viscosity Type    :     100  mPa s 
Chemical Name: Cellulose ethyl ether.  
Functional Category: Viscosity-increasing agents, tablet binder, tablet Polymer. 
Application in Pharmaceutical Formulations: 
Drug and Excipients Profile 
 
Department of Pharmaceutics.                                                                                        Page51
 
¾ Used as a hydrophobic coating agent for tablets & granules. Ethyl cellulose coatings 
are used to modify the release of a drug, to mask unpleasant taste & to improve 
stability. 
¾ Used as a matrix former to produce modified release tablets. 
¾ High viscosity grades are used in drug micro-encapsulation. 
¾ Used as a SR tablet coating material in a concentration of 3-5%. 
¾ Used as thickening agent in topical formulations. 
Description:It is a tasteless, free flowing, white to Slightly Off-White Powder. 
Viscosity: Viscosity type 100 mPa s. 
Spesifications: 
Ph             :   5 - 8 
Viscosity:   80   -    120 
Loss on drying:  5.0 max 
Hydroxpropoxy Content:    8.0   -    12.0 
Stability & Storage Conditions: Storage Conditions: Store containers sealed and in dry 
place. Keep away from heat or sunlight. 
 
 
     5.3 EXCIPIENTS PROFILE 
 
1. STARCH 
Non-Proprietary Name:  
BP               : Maize starch, Potato starch, Wheat starch, Rice starch, Tapioca starch. 
Ph Eur         : Maydis amylum, Solani amylum, Tritici amylum, Oryzae amylum. 
USP NF      : Corn starch, Potato starch, Wheat starch. 
Synonyms:  Amido, amidon, amilo, amylum.  
Chemical Name: Starch. 
Empirical Formula:  C6H10 O5.  
Molecular Weight: 50,000-160,000. 
Functional Category: Glidant and disintegrant; tablet and capsule; tablet binder.  
Application in Pharmaceutical Formulation / Technology:  
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It is used as an excipient primarily in oral solid-dosage formulations as a binder, 
diluent, and disintegrant. In tablet formulations, freshly prepared starch paste is used at 
concentration of 5-25% w/w as a binder. Commonly used tablet disintegrants at 
concentrations of 3-15%.   
Description: It occurs as an odorless and tasteless, fine white-colored powder comprising 
very small spherical or ovoid granules whose size and shape are characteristic for each 
botanical variety.    
Moisture Content: 18%for potato starch 
Swelling temperature: 640C 
Solubility: Practically insoluble in cold ethanol (95%) and in cold water.  
Stability and Storage Condition:  Stable and stored in air tight container in a cool and dry 
place. 
 
2. MAGNESIUM STEARATE 
Non-Proprietary Name:  
BP          : Magnesium Stearate  
Ph Eur    :  Magnesii Stearas 
USP NF  : Magnesium stearate  
Synonyms: E572, Hy Qual, Magnesium octadecanoate, stearic acid magnesium salts.  
Chemical Name:  Octadecanoic acid magnesium salt  
Empirical Formula: C36H70mg O4 
Molecular Weight:  591.27 
Structural Formula: [CH3 (CH2)16 COO]2Mg 
Functional Category: It is used as tablet and capsule lubricant.  
Application in Pharmaceutical Formulation / Technology:  
¾ Used in Cosmetics, foods and pharmaceutical formulations.  
¾ Primarily used in capsules and tablets manufacturing at a concentration in between 
0.25% to 5.0%. 
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Description:  
It is a fine, white, precipitated or milled, impalpable, greasy powder of low bulk 
density, having a faint, characteristics odor and taste. It readily adheres to the skin.  
Moisture: Content: <4% 
Solubility: Practically insoluble in ethanol (95%), ether and water. Slightly soluble in warm 
benzene and warn ethanol (95%) 
Stability and Storage Condition:  Stable and stored in well  closed container in a cool and 
dry place.  
3. MICROCRYSTALLINE CELLULOSE 
Synonym:  Cellulose gel; crystalline cellulose; Avicel PH 101,102 
Empirical Formula: (C6H10O5)n.    
 Molecular weight: Approx. 36000                                                                               
 Description: Purified, partially depolymerised cellulose occurs as a white, odorless, 
tasteless, crystalline powder composed of porous particles. Available in different particle size 
grades with different properties, i.e., 101 and 102.  
Density, bulk: 0.28 gm/cm3.                                                        
Density, tapped: 0.43 gm/cm3.                                                                                  
 Solubility: Insoluble in water, dilute acids and most organic solvents. slightly soluble in 
sodium hydroxide solution.                                                                                         
Stability & Storage conditions:Stable, hygroscopic,Store in a well-closed container.                                                                                                   
Incompatibilities: None cited in the literature.                                  
Handling precautions: No restrictions.                             
Uses: Tablet binder/diluent(5-20%), tablet disintegrant(5-15%), tablet glidant(5-15%), anti-
adherent(5-20%), capsule diluents (10-30%). 
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4. TALC 
        It is hydrous magnesium silicate may contain a small amount of aluminum silicate and 
iron.                                                                            
Nonproprietary Name: Purified Talc (BP); Talc (JP); Talc (USP). 
Synonym: Atalc; hydrous magnesium calcium silicate; hydrous magnesium silicate; 
magnesium hydrogen silicate; powdered talc. 
Empirical Formula:  
        Mg6 (Si2O5)4 (OH)4 
Description: A very fine, white to grayish-white, impalpable, odorless, crystalline powder. 
Adheres readily to skin, soft to touch and free from grittiness. 
Typical Properties: 
Density, bulk: 19-24 gm/cm3. 
Density, tapped: 48-62.5 gm/cm3. 
Acidity/Alkalinity: pH= 7-10 for a 20% w/v aqueous dispersion. 
Solubility:Insoluble in water, organic solvents, cold acids and dilute alkalis.    
Stability & Storage conditions: Talc is a stable material and may be sterilized by heating at 
1600 C for not less than 1 hour. Talc should be stored in a well-closed container in a cool, dry 
place. 
Incompatibilities: Incompatible with quaternary ammonium compounds. 
Handling Precautions: Observe normal precautions appropriate to the circumstances and the 
quantity of the material handled. Talc is irritant if inhaled and prolonged excessive exposure 
may cause pneumoconiosis. Eye protection, gloves, and a respirator are recommended. 
 
Table no. 1:-Application in pharmaceutical formulation or technology: 
 
 
 
 
 
 
 
Use Concentration (%) 
Dusting powder (90-99%). 
Glidant or tablets lubricant (1-10%) 
Diluents for tablets and capsules (5-30%) 
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5. LACTOSE: 
It occurs in three forms: D-monohydrate, D-anhydrous, E-anhydrous. Commercial lactose is 
mainly the D-monohydrate. 
Chemical name: 4  –  0  -  E-D galactopyranosyl-D-D- glucopyranose.4-(E-D-galactoside)-D-
glucose. 
Empirical Formula:     Molecular Weight:   
C12H22O11 (anhydrous)    342.30 
C12H22O11H2O (monohydrate)   360.31 
 
Density (bulk):0.62gm/cm3 
Density (tapped):0.94gm/cm3 
Description: White  to  off  white  or  creamy  white  crystalline  particles  or  powder,  odorless;  
sweet-tasting. 
Solubility: It is practically insoluble in chloroform, ethanol and ether .soluble in 1in 
4.63parts of water 
Stability and Storage: Store in a well-closed container to prevent absorption of moisture and 
of odors.  Under humid conditions mold growth may occur.  Lactose may develop brown 
coloration on storage.  This reaction is accelerated by warm-damp conditions. 
Incompatibilities: A mallard type condensation is likely to occur between lactose and 
compounds with a primary amino group to form brown colored products. This reaction 
occurs more rapidly with amorphous then crystalline lactose. 
Handling precautions: Gloves mask and eye protections are recommended. 
Uses: It is used as filler, diluents in pharmaceutical preparation. 
 
 
6. COLLOIDAL SILICON DIOXIDE 
Synonyme:Aerosil; cab-o-sil ; colloidal silica ; fumed silica ; silica anhydride. 
 
Nonproprietary Name: Colloidal anhydrous silica (BP), silica colloidal is androecia (Ph 
Eur), colloidal silicon anhydrous (USP) 
 
Empirical Formula: SiO2. 
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Molecular Weight: 60.08. 
 
Density (bulk): 0.029-0.042g/cm3. 
 
Density (tapped):0.05g/cm3. 
 
Acidity/Alkalinity: pH= 3.5-4.4 (4% aqueous dispersion) 
 
Solubility: Practically insoluble in organic solvent, water and acids; soluble in hot solution of 
alkali hydroxide. It forms a colloidal dispersion in water. 
 
Description: It is submicroscopic fumed silica with a particle size of 15nm. It is light, loose, 
bluish white colored, odorless, tasteless powder. Several grades of colloidal silicon dioxides 
are commercially available. 
 
Functional Category: Adsorbent; anticacking Agent; emulsion stabilizer, glident; 
suspending agents; disintegrants; thermal stabilizers; viscosity increasing agents. 
 
Application in Pharmaceutical Formulation or Technology: 
 
Use           Concentration (%) 
Aerosols     :  0.5-2.0 
Emulsion stabilizer    :  1.0-5.0 
Glidants     :  0.1-0.5 
Suspending and thickening agents   :            2.0-10.0 
 
Stability and Storage Conditions: Aerosil is hygroscopic but adsorb large quantity of water 
without liquefying. Viscosity-increasing property is depends on pH.Aerosil powder should be 
stored in a well-closed container. 
 
Incompatibilities: Incompatible with diethylstilbestrol preparations.  
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METHODOLOGY 
                 
Table No 2: Materials Used 
S.No Materials Used Monograph Sources 
1. Trimetazidine HCL BP Sharon Bio-Medicine 
LTD. 
2. Ethyl Cellulose USP Feicheng Rutai Fine 
Chemicals CO.Ltd. 
3. Metalose I.P. Arihant trading Co.Ltd. 
4. Hydroxy propyl methyl 
cellulose K-15CR 
I.P. Shineltsu LTD Japan. 
5. Lactose I.P. Berje, Chemical, 
Mumbai 
6. M.C.C. I.P. Relience cellulose Pvt. 
Ltd. 
7. P.V.P.K.30 I.P. Jyoti Associated Indore 
8. Magnesium stearate I.P. Loba Chemie Pvt.Ltd. 
9. Talc I.P. J.B. Chemical. 
10. Pregelatinised Starch  I.P. Loba Chemie Pvt.Ltd. 
11. HCL ------- Laboratory. 
12. Isoprpyl alcohol ------- Laboratory. 
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Table No 3: Instruments Used 
 
S.No Types Manufactured by 
1. Digital Weighing Balance Ohaus Corp. Pine Brook, NJ, USA. 
2. Hot air oven Unilab, India. 
3 Sieve No; # 12, 16,20, 
60,100. 
Shreeji, Pharmaceutical, Scientific & 
Laboratory Instruments., India. 
4. Compression Machine Cadmach Machineries Pvt. Ltd., Ahmedabad, 
India. 
5. Roche Friabilator Indian Equipment Corporation, Bombay. 
6. Monsanto Hardness Tester Rupa Industries, India. 
7. Dissolution Test Apparatus Electrolab, Model-TDT-08L, USP. 
8. U.V-Spectrophotometer Shimadzu Corporation, Japan. 
9. Fourier Transform Infra 
Red Spectroscopy (FTIR) 
Nexus-870, Thermo Nicolet, Manisha lab. 
10. Distillation Apparatus Borosil, India. 
11. Water Bath Unilab, India. 
12. Sonicator Spincotech Pvt.Ltd., Italy. 
13. pH-meter Elico Ltd. Hyderabad, India. 
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6.1 Identification of drug (Trimetazidine HCL) sample:  
         It was confirmed by  
¾ Melting point  
¾ FT-IR spectral analysis 
¾ UV absorption maxima 
6.1.1. Melting point determination 
         Melting point is the temperature at which the pure liquid and solid exist in 
equilibrium. In practice, it is taken as equilibrium mixture at an external pressure of 1 
atmosphere; this is sometimes known as normal melting points. The Thiel’s tube 
method of melting point determination in liquid paraffin was used in the present 
study. Melting point was found to be in the range of 2270C which was in compliance 
with the official value. 
6.1.2. FTIR Spectra:  
         IR spectra of drug in KBr pellets at moderate scanning speed between 4000-
400 cm-1 was carried out using FTIR (Jasco FTIR 6100 type A). The peak values 
(Wave number) and the possibility of functional group shown in spectra which 
compare with standard value. The comparison of these results with Trimetazidine 
HCL chemical structure shows that the sample was pure Trimetazidine HCL.(Figure 
No.7). 
6.1.3. UV absorption maxima of Trimetazidine HCL: 
UV scanning was done for 10 mcg/ml drug solution from 200-400nm in 
phoushphate buffer 6.8 as a blank using double beams UV/VIS spectrophotometer. 
The wavelength maximum was found to be at 269 nm (Figure No.11).  
 
6.2. Characterization of Drug: 
6.2.1  Physical description of Trimetazidine HCL: - 
Organoleptic properties: 
 Trimetazidine HCL is White or almost white crystalline  powder, odorless, slightly 
hygroscopic. 
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 Solubility: very soluble in water, sparingly soluble in ethanol and practically 
insoluble in ether. 
Melting point: Its melting point found to be 227oC. 
 
6.3 Drug Excipients Compatibility study: 
        Compatibility of the drug with recipients was determined by FT-IR spectral 
analysis, this study was carried out to detect any changes on chemical constitution of 
the  drug  after  combined  it  with  the  excipients.  The  samples  were  taken  for  FT-IR  
study. 
 
6.4 Preparation of buffers: 
6.4.1 Preparation of acidic buffers:- 
x Preparation of 0.2 M hydrochloric acid: 
          HCL diluted with water to contain 7.292 gm of HCl in 1000ml.  
x Preparation of 0.2 M sodium hydroxide solution- 
          Dissolve 8.0 g of sodium hydroxide pallets in 1000 ml of distilled water. 
 
6.4.2 Preparation of phosphate buffer:  
x Preparation of 0.2 M potassium dihydrogen phosphate solution- 
Dissolve 27.213 g of potassium dihydrogen phosphate in 1000 ml of distilled            
water to get 0.2 M potassium dihydrogen phosphate. 
 
x Preparation of 0.2 M sodium hydroxide solution- 
          Dissolve 8.0 g of sodium hydroxide pallets in 1000 ml of distilled water. 
 
x Preparation of phosphate buffer pH 6.8 -  
Place 50 ml of 0.2 M potassium dihydrogen phosphate and add 5.6 ml of 0.2 
M   of sodium hydroxide. Dilute with distilled water to make up the volume up 
to 200ml. 
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6.5 Preperation of Standard Calibration curve of Trimetazidine HCL- 
Weigh accurately 100mg of Trimetazidine Hcl WS into a 100-ml volumetric 
flask;Dissolve dilute to volume with phoushphate buffer pH.6.8 From the stock 
solution 10 ml was further diluted to 100 ml with purified water. Then from this 
solution aliquots of 0.3, 0.6, 0.9, 1.2, 1.5, 1.8, 1.4, 1.6, 1.8 and 2 ml were pipette out 
and made up to 10ml with phoushphate buffer pH 6.8 The Absorbance of above 
solution was measured at 269 nm by U.V.Spectrophotometer.  
        The spectrum peak point graph of absorbance of Trimetazidine HCL versus 
wave length was shown in Figure No.12. 
         
6.6 Evaluation of Powder and Grannuals: 
6.6.1 Angle of repose  
Flowability of different batch of granules was determined by calculating 
angle of repose by fixed height method. A funnel with 10 mm inner diameter of stem 
was fixed at a height of 2 cm. over the platform. About 10 gm of sample was slowly 
passed along the wall of the funnel till the tip of the pile formed and touches the steam 
of  the  funnel.  A  rough  circle  was  drawn  around  the  pile  base  and  the  radius  of  the  
powder cone was measured.  
Angle of repose was calculated from the average radius using the following 
formula.                                   
                                                       T = tan (h/r) 
Where, T = Angle of repose, h = Height of the pile, r = Average radius of the powder 
cone. 
 
6.6.2. Bulk density and Tapped density 
        An accurately weighed quantity of the powder (W) was carefully poured into the 
graduated cylinder and the volume (vo) was measured then the graduated cylinder was 
closed with lid, set into the density determination apparatus (bulk density apparatus, 
electro  lab,  Mumbai).  The  density  apparatus  was  set  for  500  taps  and  after  that,  the  
volume (Vf) was measured and continued operation till the two consecutive readings 
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were equal. The bulk density, and tapped density were calculated using the following 
formulas. 
Bulk density   = W/Vo 
Tapped density  = W/Vf 
       Where,    Vo  = initial volume 
                 Vf   = final volume. 
 
6.6.3 Compressibility index: 
        The Compressibility index and Hausner ratio are measures of the propensity of a 
powder to be compressed. As such, they are measures of the relative importance of 
interparticulate interactions. In a free-flowing powder, such interactions are generally 
less significant, and the bulk and tapped densities will be closer in value. For poorer 
flowing materials, there are frequently greater interparticle interactions, and a greater 
difference between the bulk and tapped densities will be observed. These differences 
are reflected in the Compressibility Index and the Hausner Ratio.  
The compressibility index and Hausner ratio may be calculated using 
measured values for bulk density (  bulk) and tapped density (  tapped) as follows:  
 
                                             tapped -  bulk 
   Compressibilty Index =       -----------------   X 100 
         tapped 
                                                  
6.6.4 Hausner Ratio: 
It provides an indication of the degree of densification which could result 
from vibration of the feed hopper.  
 
                            Tapped Density 
  Hausner Ratio = ----------------------- 
                            Bulk density 
 
Lower Hausner ratio  Better flowability, 
 Higher Hausner ratio  Poor flowability  
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6.7 Formulation of Trimetazidine HCL Matrix Tablets: 
Each quantity mentioned will be taken in mgs, 
Total weight of the tablet = 180mg 
Each tablet contains      = 35mg of the Trimetazidine HCL 
 
 
Table No.4: Formulation of Trimetazidine HCL Matrix Tablets 
 
  
Ingrdients 
Mg/tablet 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
 
F9 
 
Trimetazidine Hcl 35 35 35 35 35 35 35 35 35 
Metalose 35 52.5 70 ----- ----- ----- 35 35 35 
H.P.M.C.K15CR ----- ----- ----- 35 52.5 70 8.75 17.5 35 
Ethyl Cellulose 7 7 7 7 7 7 7 7 7 
Pregelatinised 
Starch 
27 27 27 27 27 27 27 27 27 
Microcrystaline 
Cellulose 
18 18 18 18 18 18 18 18 18 
Lactose 44 26.5 9 44 26.5 9 35.25 26.5 9 
P.V.P.K.30 7 7 7 7 7 7 7 7 7 
I.P.A. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Aerosil 1 1 1 1 1 1 1 1 1 
Talc 3 3 3 3 3 3 3 3 3 
Mg.Stearate 3 3 3 3 3 3 3 3 3 
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MANUFACTURING PROCEDURE 
WET GRANULATION METHOD: 
DRY MIXING:  
                        Weighed accurate quantity of trimetazidine,metalose HPMC 
K15CR,Ethyl cellulose,pregelatinised starch,Microcrystalline cellulose and Lactose 
were sifted through 40#. The above ingredients are taken in a matar and pestle and 
mixed thoroughly for 10 minutes. 
BINDER PREPARATION: 
                                            Accurately weighed quantity of Iso propyl alcohol taken in 
a glass beaker and weighed quantity of PVP K 30 are added gradually with uniform 
mixing with glass rod for 15 minutes until the solution getting clear saturation. 
WET MIXING BINDER ADDITION: 
                                                               The prepared binder solution was added in to 
the dry mixing materials with continuous trituration to form a coherent mass. If 
required additional quantity of Iso propyl alcohol was added until to get a uniform 
granules.  
DRYING: 
                  After wet granulation procees wet mass sieved through 10# mesh and 
dried in oven at 60ƕ c.Continue the drying process until the granules reaching the 
LOD of 2%. After reaching thr desired LOD stop the drying process and sieved 
through 22# 
LUBRICATION:  
                          Presieved lubrication materials of aerosil, talc, magnesium stearate 
were added in to the above dried granules and mixed thoroughly. 
COMPRESSION: 
                           The lubricated granules are compressd by 10/32 inchess(7.93mm)  
size and circular shape deep cocave punches.Hardness is maintained NLT 4kg/cm4. 
And the average weight of 180 mg per tablet. 
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      Addition of Binders Solution 
 
 
                                                                      # 10 Screen 
 
                                                                         
                                                                          Drug in Hot air oven at 60°C                     
                                                                          
                                            
                                                                            # 22 Screen & Adding Lubricant 
                                                                         
 
                                                                                          
                                                                        
   
                                                       
 
                                                                
                                                                        
 
 
 
Figure No. 6:-Schematic representation of preparation of Matrix Tablet 
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6.8. COATING PROCEDURE 
 
           Weigh accurately H.P.M.C 6 CP and Ethyl Cellulose and mixed in half portion 
of I.P.A. Dissolve titaneous oxide, yellow iron oxide, talc in half portion of I.P.A. mix 
well half portion of metylene chloride was added in above solution.Dissolve PEG 
6000 in half portion of methylene chloride and added to above solution and stirred 
well.      The compressed tablets are loaded in to the coating pan and coating solution 
are sprayed uniformly to get a desird weight buil up. 
 
 
Table No. 5:-Coating Formula 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No. 
 
Ingradients 
 
Quantity 
1. H.P.M.C. 6 cp 5 mg 
2. Etyl Cellulose 0.5 mg 
3. Polyethylene Glycol 1 mg 
4. Titanium Dioxide 1 mg 
5. Yellow Iron Oxide 0.5 mg 
6. Talcum 1 mg 
7. I.P.A. 0.15 ml 
8 Methylene Chloride 0.2 ml 
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6.9 Evaluation of Tablets: 
        All the prepared Sustained release tablets were evaluated for following official 
and unofficial parameters. 
 Weight Variation 
  Thickness 
 Hardness Test 
 Friability Test 
 Drug content 
 Dissolution Study 
 
 
6.9.1. Weight variation: 
        Twenty tablets were randomly selected from each batch and individually 
weighed. The average weight and standard deviation of 20 tablets was calculated. The 
batch passes the test for weight variation test if not more than two of the individual 
tablet weights deviate from the average weight by more than the percentage shown in 
Table no.10 and none deviate by more than twice the percentage shown. 
 
Table No.6:- Percentage deviation allowed under weight variation 
 
Percentage deviation allowed under weight variation test. 
Average weight of tablet (X mg) Percentage deviation 
X < 80 mg 
                
                      80 < X < 250 mg 
 
X > 250 mg 
10 
 
7.5 
 
5 
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6.9.2. Thickness 
        Twenty tablets were randomly selected from each batch and there thickness and 
diameter was measured by using digital vernier caliper. 
 
 
6.9.3 Tablet Hardness 
        The crushing strength Kg/cm2 of prepared tablets was determined for 10 tablets 
of each batch by using Monsanto tablet hardness tester. The average hardness and 
standard deviation was determined. The results are shown in Table No.10 
. 
 
6.9.4. Friability: 
Method: 
       Twenty tablets were weighed and placed in the Electrolab friabilator and 
apparatus was rotated at 25 rpm for 4 minutes. After revolutions the tablets were 
dedusted and weighed again. The percentage friability was measured using the 
formula, 
 
 
% F = {1-(Wt/W)} ×100 
 
 
Where,  % F  = friability in percentage 
          W  = Initial weight of tablet 
          Wt   = weight of tablets after revolution 
 
The results are shown in Table 10. 
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6.9.5 Assay Procedure: - 
 
Standard preparation: 
Transfer an accurately weighed quantity of about 40 mg of trimetazidine HCL to 200 ml 
volumetric flask. Dissolve and dilute to volume with 0.1 N HCL and makeup the volume. 
 
 
Test preparation: 
Crush 20 tablets and weigh accurately 40 mg of powder equivalent to the trimetazidine 
HCL into  200  ml  volumetric  flask.  Dissolve  and  dilute  to  the  volume with  0.1  N HCL 
and makeup the volume. Filter the test preparation through 0.45µ filter paper. 
Measure the absorbance of standard and test at 269 nm and calculate trimetazidine HCL 
by the following equation: 
 
 
                       Absorbance of sample       wt. of STD       200         avg. wt 
% ASSAY=      ----------------------------     x   -------------   x   ------   x   --------- x potency 
                       Absorbance of standard          200           test. Wt        L.C. 
 
The results are shown in Table No.10  
 
6.9.6. In Vitro Dissolution Studies: 
        In Vitro dissolution study was carried out using USP II apparatus (paddle 
apparatus) in 900ml of phosphate buffer pH 6.8 for 8 hours. The temperature of the 
dissolution medium was kept at 37± 0.5oC and the paddle was set at 100 rpm. 10 ml 
of sample solution was withdrawn at specified interval of time. The absorbance of the 
withdrawn samples was measured at Ȝmax 269nm using UV visible spectrophotometer. 
The concentration was determined from the standard curve of Trimetazidine HCL 
prepared in phosphate buffer pH 6.8 at Ȝ max 269nm. Cumulative percentage of drug 
release was calculated using the equation obtained from a standard curve.  
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6.9.7 Swelling Index 
        The swelling index of tablets was determined in phosphate buffer pH 6.8 at room 
temperature. The swollen weight of the tablets was determined at predefined time 
intervals. The swelling index was calculated by the following equation: 
 
Swelling index WU  =   (W1 – W0)   x 10 
                                            W0 
 
 
                   Where, Wt = Weight of tablet at time t. 
                     W0  = Initial weight of tablet 
. 
6.9.8 Modeling of Dissolution Profiles   
        In vitro dissolution has been recognized as an important element in drug 
development under certain assessment of Bioequivalence. Several theories/kinetics 
models describe drug dissolution from immediate and modified release dosage forms. 
There are several models to represent the drug dissolution profiles where ft is a 
function of ‘t’ (time) related to the amount of drug dissolved form the pharmaceutical 
dosage system (Costa and Lobo,2001).Whenever a new solid dosage form is 
developed or produced, the drug release/dissolution from solid pharmaceutical dosage 
form is necessary to ensure that the drug dissolution occurs in an appropriate manner.                                       
 
          The quantitative interpretation of the value obtained from the dissolution assay 
is facilitated by mathematical equation which translates the dissolution curve in 
function of some parameters related with the pharmaceutical dosage forms.   
 
In the present study, data of the in vitro release  were  fitted  to  different  
equations  and  kinetic  models  to  explain  the  release  kinetics  of  Trimetazidine  HCL  
from the matrix tablets. The kinetic models used were a Zero order equation, Higuchi 
release. 
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Drug release models: 
To describe the kinetics of the drug release from the matrix tablet batches, 
mathematical models such as zero-order, first order, Higuchi, Hixon-crowell models 
were used. The criterion for selecting the most appropriate model was chosen on the 
basis of the goodness-or fit test.  
The zero-order kinetic describes the systems in which the drug release rate is 
independent of its concentration. The first order kinetic describes the systems in 
which the drug release rate is concentration dependent. Higuchi described the release 
of drug from an insoluble matrix as square root of time dependent process.  
In case of the Higuchi square root model gives the drug release from a 
planer surface of an insoluble heterogeneous matrix by diffusion through the 
intragranular openings created by porosity of the matrix tablet.  
 
 
6.10 Stability Studies 
 Selected formulations were subjected to stability studies as per I.C.H. 
Guidelines. 
Following conditions were used for stability studies 
 30qC/65 % RH analyzed till a period of 30 days 
 40qC/75 % RH analyzed till a period of 30 days 
Following parameters  were check for stability studies 
Hardness, friability, drug content and in vitro release. 
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RESULTS AND DISCUSSION 
 
7.1 IDENTIFICATION OF DRUG:- 
 
7.1.1 FTIR Spectra:  
         IR spectra of drug in KBr pellets at moderate scanning speed between 4000-
400 cm-1 was carried out using FTIR (Jasco FTIR 6100 type A). The peak values 
(Wave number) and the possibility of functional group shown in spectra which 
compare with standard value.  
  The  comparison  of  these  results  with  trimetazidine  HCL chemical  structure  
shows that the sample was pure Trimetazidine HCL. Figure No.7. 
 
 
7.1.2 UV absorption maxima of Trimetazidine HCL: 
   UV scanning was done for 10 mcg/ml drug solution from 200-400nm in 0.1 
N HCL as a blank using double beams UV/VIS spectrophotometer.   The wavelength 
maximum was found to be at 269nm (Figure No. 11).  
 
 
7.2 Drug Excipients Compatibility study: 
                Compatibility of the drug with recipients was determined by FT-IR spectral 
analysis, this study was carried out to detect any changes on chemical constitution of 
the drug after combined it with the excipients. 
                The samples were taken for FT-IR study. (Figure No. - 8, 9, 10). 
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Figure No. 7:- IR Spectrum of Pure Drug (Trimetazidine HCL) 
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7.2.1 Drug Excipients Compatibility study: 
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Figure No. 8:- IR Spectrum of drug + HPMC K15 CR 
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Figure No. 9:- IR Spectrum of Drug + Metalose 
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Figure No.10:-IR Spectrum of Drug + Ethyl cellulose 
   
 
  IR spectra studies revealed that the drug and polymers used were compatible. 
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7.3 Determination of Ȝ max: 
 
 
 
Figure No.11:-Absorbance Maxima of Trimetazidine HCL 
   
7.4 Calibration Curve of Trimetazidine HCL 
 
Table No. 7:- Calibration curve of Trimetazidine HCL 
 
 
 
 
 
 
 
 
 
 
 
Concentration Absorbance at 
269nm 
0 0 
3 0.049 
6 0.105 
9 0.162 
12 0.217 
15 0.266 
18 0.321 
21 0.386 
24 0.433 
27 0.495 
30 0.587 
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Figure No. 12:- Calibration Curve of Trimetazidine HCL 
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7.5 Evaluation of Powders:- 
7.5.1 Preformulation Studies:- 
 
Table No.8:- Preformulation studies of pure drug and polymers 
 
Parameter 
Results 
Trimetazidine 
HCL 
HPMC-K-15 
CR 
Metalose Etyl Cellulose 
Angle of Repose 24 22 19 26 
Bulk Density 
(gm/cm3) 
0.46 0.31 0.35 0.60 
Tapped Density 
(gm/cm3) 
0.72 0.52 0.59 0.77 
Compressibility 
Index 
36.11 40.34 40.67 22.07 
Hauser’s Ratio 1.56 1.60 1.68 
 
1.28 
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Table No. 9:- Preformulation studies of blend 
 
 
 
 
 
            Preformulation study was done initially and results directed for the further 
course of formulation. Based on Preformulation studies different batches of 
Trimetazidine HCL (F1 to F9) were prepared using selected excipients. 
 
 Powders were evaluated for tests Angle of repose, Bulk density, tapped 
density, compressibility index, Hausner ratio before being punched as tablets.  
 
 
 
 
 
 
 
 
 
BATCH 
NO. 
BULK 
DENSITY 
(g/ml) 
TAPPED 
DENSITY 
(g/ml) 
COMPRSI 
BILITY 
(%) 
HOUSNER 
RATIO 
ANGLE OF 
REPOSE 
(°) 
F1 0.314 0.389 19.2 1.237624 250 
F2 0.368 0.426 13.6 1.157407 180 
F3 0.399 0.476 16.2 1.193317 200 
F4 0.354 0.416 17.51 0.86 29011’ 
F5 0.399 0.476 16.2 1.193317 20o12’ 
F6 0.421 0.512 17.7 1.215067 230 
F7 0.458 0.534 14.3 1.166861 200 
F8 0.316 0.409 29.43 0.77 31016’ 
F9 0.366 0.457 24.86 0.80 240 
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7.5.2 Physico-Chemical Evaluation of Matrix Tablets:  
       The results of the thickness, Hardness, weight variation, drug content, friability, 
disintegration time of tablet are shown in Table No.10. 
 
 
Table No. 10:- INPROCESS RESULTS: Thickness, weight variation, Hardness, 
Friability and Drug content 
 
 
BATCH 
NO. 
WEIGHT 
VARIATION  
FRIABILITY 
(%) 
HARDNESS 
(kg/cm2) 
THICKNESS 
(mm) 
DRUG 
CONTENT 
(%) 
F1 ±4.0 0.12 4.5 3.9 96.20 
F2 ±2.0 0.19 5 4 97.26 
F3 ±3.0 0.39 5 4.1 98.93 
F4 ±2.55 0.14 5 4 97 
F5 ±2.0 0.24 5 3.9 99.89 
F6 ±3.44 0.11 5.5 3.8 98.53 
F7 ±2.0 0.43 4 4.1 97.11 
F8 ±5.66 0.16 5 3.9 97 
F9 ±5.22 0.18 5.5 3.8 96.00 
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 7.5.3 In Vitro Dissolution Studies 
          
            Table  No.11  shows  the  data  for  in  vitro  release  of  Trimetazidine  HCL  from  
matrix tablet of batches F1, F2, F3, F4, F5, F6, F7, F8 and F9 respectively. 
           As follows the dissolution profiles shows the comparative release profile of  
Trimetazidine HCL with different concentration  of  different polymer from batches 
F1, F2, F3, F4, F5, F6, F7, F8, F9 of matrix tablet.  
 
Table No. 10 :- Cumulative % Release of Drug of various Formulations 
 
 
 
 
 
 
  
 
 
 
 
 
 
Time(Hr) F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
1 40.5 41.1 42.31 38.25 45.04 36.83 33.78 37.47 34.61 
2 54.44 59.07 58.14 48.75 54.14 51.01 45.73 55.06 50.36 
4 80.51 84.25 81.38 81.18 78.1 73.38 67.16 77.81 68.95 
6 88.23 90.08 89.99 89.99 85.31 84.43 72.93 85.52 72.98 
8 91.19 92.86 92.95 92.95 86.84 89.96 85.02 87.75 80.77 
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7.5.4 Percentage drug Release Profile of F1 to F9 
 
 
 
 
 
 
Figure No.13:- Graph of the Cum. % drug release versus Time (hrs) 
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7.5.4. % Swelling Index of Tablets of Batch F1 toF9 
 
 
Table No.11:- % Swelling Index of Tablets of Batch F1 toF9 
 
 
 
Figure No. 14:- Comparison of % swelling index of various formulations 
 
 
 
Batch 
TIME (HRS) 
0 1 2 3 4 5 6 
F1 0 32.23 41.38 54.32 63.78 74.12 81.2 
F2 0 49.25 61.54 72.90 82.37 92.54 100.22 
F3 0 29.09 39.45 51.32 61.12 71.97 80.35 
F4 0 39.21 51.92 63.76 72.52 84.2 96.56 
F5 0 45.65 53.35 64.32 75.45 80.09 94.58 
F6 0 56.73 66.76 77.72 82.26 94.60 101.25 
F7 0 39.06 47.96 55.32 65.34 76.09 87.11 
F8 0 25.87 36.54 47.86 57.98 69.96 72.44 
F9 0 26.76 40.98 49.54 59.06 69.78 75.99 
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7.5.5 Kinetic assessment of Extended release Matrix tablet containing 
Trimetazidine HCL- 
 
Huguchi Modeling - 
 
Table No. 12:- Huguchi Modeling  
                                                                                     
BATCHES R2 VALUE 
(ZERO ORDER) 
R2 VALUE 
      (HUGUCHI) 
F1 0.809 0.971 
F2 0.787 0.961 
F3 o.798 0.969 
F4 0.802 0.975 
F5 0.768 0.955 
F6 0.851 0.988 
F7 0.865 0.991 
F8 0.802 0.968 
F9 0.807 0.973 
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Figure No. 15:- Huguchi Modeling 
 
 
 
          
 
 
              Figure No. 16:- Zero order Modeling 
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7.6 Stability Study of Optimized Formulation: -  
      As per I.C.H. Guidelines 
 
 
Table No. 13: Stability studies of formulation F-9 stored at 30qC/65 % RH 
 
Time (hr) 
Cumulative % Drug Release 
Initial After 30 Days 
0 0 0 
1 34.61 34.01 
2 50.36 50.98 
4 68.95 67.33 
6 72.98 71.61 
8 80.77 80.11 
 
Hardness 
 
5.5 5.5 
 
Friability 
 
0.18 0.17 
Drug 
content 
 
96 95.92 
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Table No-14:- Stability studies of formulation F-9 stored at 40qC/75 % RH 
 
 
 
 
 
 
 
 
 
Time (hr) 
Cumulative % Drug Release 
Initial After 30 Days 
0 0 0 
1 34.61 33.53 
2 50.36 50.12 
4 68.95 66.65 
6 72.98 72.53 
8 80.77 79.78 
 
Hardness 
 
5.5 5.5 
 
Friability 
 
0.18 0.18 
Drug 
content 
 
96 94.99 
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SUMMARY AND CONCLUSION 
  
 
            Oral route of drug administration is oldest and safest mode of drug 
administration. It posses several advantages. It provides accurate dosing without 
assistantship of administration. In conventional oral drug delivery system, there is little or 
no control over release of drug, and effective concentration at the target site can be 
achieved by administration of grossly excessive dosage form. Sustained release 
technology is relatively new field and as a consequence, research in the field has been 
extremely fertile and has produced many discoveries. With many drugs, the basic goal is 
to achieve a steady state blood level that is therapeutically effective and non-toxic for an 
extended period of time. The design of proper dosage form is an important element to 
accomplish this goal. 
 
 
          Trimetazidine HCL is Vasodilator with half life of 6 hours and requires 
multiple daily doses to maintain adequate plasma concentrations. So it is selected to 
prepare  an  extended  release  Matrix  tablet.  The  objective  of  this  present  study  is  to  
develop an extended release Matrix tablet of Trimetazidine HCL which releases the drug 
in an extended manner over a period of 8 hours, by using different polymers and study on 
polymer concentration effect on release pattern. 
 
        The present study was undertaken with an aim to formulate develop and evaluate 
Trimetazidine HCL extended release matrix tablets using different polymers as release 
retarding agent. 
 
 
        Preformulation study was done initially and results directed for the further course of 
formulation. Based on Preformulation studies different batches of Trimetazidine HCL 
were  prepared  using  selected  excipients.  Powders  were  evaluated  for  tests  Angle  of  
repose, Bulk density, tapped density, compressibility index, and Hausner ratio before 
being punched as tablets.  
 
 
         IR spectra studies revealed that the drug and polymers used were compatible. 
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        Various formulations of sustained release matrix tablets of Trimetazidine HCL were 
developed using various polymers viz, HPMC K-15CR, Hypermellose, Ethyl Cellulose in 
different proportions and combinations by Wet Granulation technique. The tablets were 
evaluated for physical characterization, in vitro swelling behavior, in vitro release study 
and stability studies. 
 
        Observations of all formulations for physical characterization had shown that, all of 
them comply with the specifications of official pharmacopoeias and/or standard 
references. 
 
        Results of in vitro release profile indicated that formulation F9 was the most 
promising formulation as the extent of drug release from this formulation was high as 
compared to other formulations. Results of in-vitro swelling study indicate that the 
formulation F9 was having considerable swelling index. 
  
 
        Stability study was conducted on tablets of Batch F9 stored at 300C (Room 
Temperature) and 400C for one month. Tablets were evaluated for hardness, friability, in-
vitro release profile and drug content. After one month no significant changes were 
observed in any of the studied parameters during the study period, thus it could be 
concluded that formulation was stable. It was concluded that the tablets of batch F9 had 
considerable swelling behaviors and in vitro drug release. Percentage drug release in 8 hr 
is 80.77.  It was observed that tablets of batch F9 followed the Huguchi release profiles.  
 
        From the above results and discussion it is concluded that formulation of Extended 
release matrix tablet of Trimetazidine HCL containing HPMC K-15 (19.44%) and 
Hypermellose (19.44%), Ethyl cellulose (19.44%) batch F9 can be taken as an ideal or 
optimized formulation Extended release matrix tablet for 8 hour release as it fulfills the 
requirements for extended release matrix tablet.  
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